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SUMMARY 
 
Regulatable control of gene expression in the mammalian brain is of tremendous 
importance in understanding the role of neural circuits in the processing, storage and 
retrieval of information. To understand the fundamental molecular mechanisms 
underlying these processes, there is the need to develop diverse molecular genetic tools 
that allow for conditional gene regulation in the central nervous system. 
To address this issue, we have developed recombinant adeno-associated viruses 
(rAAVs) equipped with tetracycline (Tet)-controlled genetic switches to inducibly and 
reversibly manipulate neural circuits, in the mammalian brain. The present work focused 
on three objectives: In the first part, long-term, Tet-controlled gene regulation in neurons 
was investigated. In this part, the rAAV system was used to study the kinetics of Tet-
controlled gene regulation in vitro and in vivo using the firefly luciferase reporter assay. 
Furthermore, repeated cycles of gene activation and inactivation in vivo were also 
demonstrated. In the second part, inducible, subregion- and cell type-restricted gene 
recombination and gene knockout in the mouse brain was investigated by employing the 
rAAV system expressing the site-specific Cre recombinase enzyme and a red fluorescent 
marker protein under Tet control. Conditional and region-specific gene recombination in 
transgenic reporter mice was carried out by either targeting the viruses to the 
hippocampus, cortex or both. Gene recombination occurred in these regions only upon 
Doxycycline (Tet derivative) injection. With the rAAV and Tet-controlled inducible gene 
expression systems, the N-Methyl-D-aspartate (NMDA) receptors were knocked out in 
the barrel field. We clearly demonstrated by electrophysiology that loss of NMDA 
receptors took place after one week of Dox treatment. With the inducible knockout 
approach, we are currently investigating the function of NMDA receptors in acquisition 
and maintenance of associative learning and memory.  
In the last part, inducible and reversible silencing of synaptic transmission was 
investigated with the use of tetanus toxin light chain (TeTxLC). By reversible silencing 
of synaptic transmission with TeTxLC, the role of neurons from different brain regions in 
memory consolidation processes and behavior will be investigated. With this approach, 
we have demonstrated that TeTxLC expression results in silencing of synaptic 
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transmission. Moreover, by expressing the TeTxLC in the striatum of the mouse brain, a 
behavioral phenotype was produced, which was reversed by Dox administration. The 
original TeTxLC has a long half-life thus, very slow off rate. To reduce the half-life of 
the TeTxLC, new variants of TeTxLC were generated, named fast one (F1-TeTxLC) and 
fast two (F2-TeTxLC). With these new variants of TeTxLC, we observed that reversible 
silencing of synaptic transmission took place within 3 weeks with F1-TeTxLC and less 
than two weeks with F2-TeTxLC in vivo. We also demonstrated synaptic silencing in 
organotypic brain slices 24-48 hours after Dox treatment in vitro. 
A combination of these newly developed genetic tools will be of great advantage 
to investigate the role of neural circuits in learning, memory consolidation and behavior. 
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ZUSAMMENFASSUNG 
Um besser verstehen zu können, wie neuronale Schaltkreise Informationen prozessieren, 
speichern und abrufen, ist es von großer Bedeutung, die Expression bestimmter Gene im 
Gehirn regulieren zu können. Daher bedarf es der Entwicklung verschiedener genetischer 
Werkzeuge um konditionale Genexpression zu ermöglichen.  
In dieser Arbeit wurden rekombinante adenoassoziierte Viren (rAAV) entwickelt, 
die mit Tetracyclin (Tet)-regulierten genetischen Sequenzen ausgestattet sind. Mit Hilfe 
dieser Technik ist es möglich, Neurone oder Netzwerke von Neuronen im Gehirn von 
Säugetieren reversibel und induzierbar zu manipulieren. Die vorliegende Arbeit 
beschäftigt sich mit drei Fragestellungen. Im ersten Abschnitt wurde über längere Zeit die 
Tet-kontrollierte Genregulation in Neuronen untersucht. In diesem Abschnitt wurde das 
rAAV-System verwendet, um die Kinetik der Tet-abhängigen Genexpression in vitro und 
in vivo mit Hilfe des “firefly luciferase” Reporter-Assays zu untersuchen.  Dabei konnte 
gezeigt werden, dass sich die Genexpression zyklisch An-und Abschalten lässt. 	  
Im zweiten Teil dieser Arbeit wurde untersucht, wie sich induzierbare Gen-
Rekombination und Gen „Knock-out“ auf spezielle Hirnregionen und Zelltypen 
eingrenzen lassen. Dafür wurde ein Tet-induzierbares rAAV-System entwickelt, welches 
neben der Sequenz-spezifischen Cre-Rekombinase auch ein rot-fluoreszierendes Protein 
exprimiert. Für die konditionale Gen-Rekombination wurden der Hippocampus, der 
Kortex oder beide Hirnregionen von transgenen Reporter-Mäusen mit Viren injiziert. Die 
Gen-Rekombination erfolgte in diesen Regionen in Abhängigkeit der Zugabe von 
Doxyciclin, eines Tet-Derivates. Darüber hinaus wurde mit diesem rAAV-System der N-
Methyl-D-Aspartat (NMDA) Rezeptor im Barrel-Kortex deletiert. Mit Hilfe 
elektrophyisologischer Studien konnte bereits eine Woche nach Dox-Gabe eine 
Reduktion des NMDAR-Levels festgestellt werden. Mit diesem System kann die 
Funktion des NMDAR bei der Erlernung und Aufrechterhaltung assoziativer 
Gedächtnisinhalte erforscht werden.  
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Im letzten Abschnitt dieser Arbeit wurde eine Methode entwickelt, mit welcher 
durch Expression der kleinen Untereinheit von Tetanus Toxin (TeTxLC) die synaptische 
Transmission reversibel und induzierbar gehemmt werden kann. Dieses System 
ermöglicht die Erforschung der Funktion spezifischer Neuronenpopulationen bei 
Prozessen der Gedächtniskonsolidierung  und des Verhaltens. Es konnte gezeigt werden, 
dass die synaptische Transmission durch Expression von TeTxLC gehemmt wird. Durch 
Expression von TeTxLC im Striatum wurde bei Mäusen ein Verhaltens-Phänotyp 
erzeugt, welcher durch Gabe von Dox revidiert werden konnte. Das anfänglich 
entwickelte TeTxLC hat eine lange Halbwertszeit und somit eine sehr langsame 
Aktivitätsabnahme. Um die Halbswertszeit des TeTxLC-Proteins zu verringern wurden  
zwei weitere Varianten des TeTxLC-exprimierenden Systems generiert, fast one (F1-
TeTxLC) und fast two (F2-TeTxLC). Mit diesen neuen Varianten konnte die Aufhebung 
der induzierten Hemmung der synaptischen Transmission signifikant verkürzt werden: 
auf drei Wochen mit F1-TeTxLC und weniger als zwei Wochen mit F2-TeTxLC. 
Darüber hinaus konnten wir synaptische Hemmung in organotypischen Gehirnschnitten 
24-48 Stunden nach Behandlung mit Dox in vitro nachweisen. 	  
Die Kombination dieser neu entwickelten genetischen Werkzeuge wird sehr 
nützlich sein zur Erforschung der Funktion neuronaler Netzwerke beim Lernen, der 
Gedächtniskonsolidierung und des Verhaltens.	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1. INTRODUCTION 
 
The mammalian brain is considered one of the most complex networks of cells on this 
planet. The cells of these networks are called neurons. In the human cerebral cortex 
alone, there are about 25 billion neurons (Pelvig et al., 2008, Herculano-Houzel, 2009). 
Each of these neurons makes up to tens of thousands of synaptic connections to other 
neurons. The central goal of neuroscience today is no longer the investigation of a single 
neuron but an ability to comprehend networks of cells that interact with each other to 
form circuits and to link these circuits to information processing and behavior. Brain 
circuits are composed of different neuronal types with diverse functions (Callaway, 
2005). At the functional level, a large number of synaptic and extra-synaptic proteins 
controls communication between synapses. With trillions of connections, the brain has a 
tremendous computational capacity to engage dedicated neuronal circuits in learning and 
memory and behavior. To understand how activity-regulated genes control the function 
of neuronal circuits at a molecular and cellular level, it is imperative to develop methods 
to inducibly inactivate any gene-of-interest in specified neuronal types, for example, by 
using the Cre-loxP-mediated gene recombination (Sauer and Henderson, 1989). 
Alternatively, dominantly acting mutant protein variants and siRNAs can be used to 
interfere with protein activity and expression levels, respectively (Gaur, 2006). To dissect 
the functional role of specific neuronal types embedded in neuronal circuits, methods are 
also needed for reversible silencing of synaptic transmission.  
To understand the functional roles of neural circuits, we have developed 
recombinant adeno-associated viruses (rAAVs) equipped with tetracycline (Tet)-
controlled genetic switches to inducibly and reversibly manipulate neurons, and thereby 
circuit function in the mammalian brain. The present study focused on three main goals: 
(1) Long-term, Dox-controlled, tTA- and rtTA-dependent regulated gene expression in 
neurons, (2) Inducible, subregion- and cell type–restricted gene expression and gene 
knockout in the mouse brain and (3) Inducible and reversible silencing of synaptic 
transmission with tetanus toxin light chain (TeTxLC).  
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1.1 Tetracycline-controlled inducible gene expression systems 
 
 
1.1.1 Genetic components of the Tet system 
 
Controlling individual gene activity in the mammalian brain is the ultimate requirement 
for correlating gene function to neuronal physiology and animal behavior (Strand et al., 
2007). From a list of different inducible gene expression systems (Gingrich and Roder, 
1998), the tetracycline (Tet)-controlled genetic switches have shown superior 
performance in different biological preparations and model animals (Gossen and Bujard, 
2002, Berens and Hillen, 2004, Sprengel and Hasan, 2007). Tet is a powerful antibiotic, 
which kills bacteria through inhibition of translation (Epe and Woolley, 1984, Hillen and 
Berens, 1994). The bacteria can mount resistance to Tet by expressing TetA resistance 
protein, a proton-[Tet.Mg]+antiporter (Yamaguchi et al., 1990). TetA is not expressed 
under regular conditions because its expression is blocked by the Tet repressor (TetR). 
Tet repressor (TetR) of the Tn10 Tet-resistance operon of Escherichia coli is a protein 
composed of 208 amino acids with 10 α-helices that make up the interaction surfaces for 
TetR dimerization, binding to the Tet operator DNA sequence (tetO) and an inducer, Tet 
or one of its derivatives such as doxycycline (Dox) (Hillen and Berens, 1994, Orth et al., 
2000). In the absence of Tet, TetR dimmer binds in the TetR and TetA promoter regions 
to the operators tetO1 and tetO2 respectively (Hillen and Berens, 1994, Sprengel and 
Hasan, 2007). The binding physically hinders transcriptional initiation at the TetR and 
TetA promoters, leading to down regulation of the expression of these two genes (Hillen 
and Berens, 1994, Sprengel and Hasan, 2007). 
Tet and Dox are the ideal inducers for controlling gene expression because they 
can rapidly distribute in different tissues in vivo (Bocker et al., 1981, Michel et al., 1984). 
Tetracyclines are widely used antibiotics with well-studied pharmacokinetics in different 
mammalian species. However, Tet derivative Dox, is preferred because it is more 
hydrophobic than Tet and can rapidly cross the blood-brain-barrier (Bocker et al., 1981, 
Michel et al., 1984). Dox concentrations required to control gene expression in vivo are 
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largely within the non-toxic range (Bocker et al., 1981, Michel et al., 1984). TetR binds 
to Tet and Dox with high affinity with the following binding constants: [Tet.Mg]+ (Ka 
~109 M-1) and [Dox.Mg]+ (Ka ~1010 M-1), which are about two to five orders of 
magnitude higher than the affinity of these drugs to the prokaryotic ribosome (Lederer et 
al., 1996). The affinity of the TetR to the tetO (Ka ~6x 109 M-1) is reduced by nearly 9 
orders of magnitude when an inducer, Tet, binds to TetR (Lederer et al., 1996). TetR also 
has a very low affinity for non-specific DNA sequences (Ka ~4x105 M-1). These 
biophysical and biochemical features make the bacterial Tet system an ideal choice for 
the reversible control of gene expression in living cells (Hillen and Berens, 1994). 
 
 
1.1.2 Tet-controlled gene expression in eukaryotic systems 
 
The basic genetic components of the Tet system as mentioned above consist of three 
essential components; TetR, tetO and Tets. These components have been modified in 
various ways for the control of gene expression in eukaryotes. For the reversible control 
of gene expression in eukaryotic cells and organisms, the C-terminal region of the TetR 
was fused to a potent transcription activation domain (VP16) derived from the herpes 
simplex virus (HSV) (Gossen and Bujard, 1992, Sprengel and Hasan, 2007). The hybrid 
protein, TetR-VP16, named the tetracycline transactivator (tTA), binds to the tetO 
sequences through the TetR domain, while the VP16 participates in the recruitment of the 
RNA polymerase II transcription initiation complex to initiate transcription (Gossen and 
Bujard, 1992, Sprengel and Hasan, 2007). In the absence of Tet, or its derivatives such as 
Dox, tTA binds to the Ptet and drives the expression of downstream genes (Tet-ON) (Fig. 
1.1 A). However, in the presence of Tet, tTA is unable to bind to Ptet (Fig. 1.1 B) 
resulting in the termination of transcription initiation at Ptet (Tet-OFF). 
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Figure 1.1 Principles of the Tet-OFF-system. (A) When the constitutively expressed tTA 
binds to Ptet, tTA activates transcription. (B) In the presence of Tet, tTA is unable to bind to Ptet, 
and Ptet-controlled gene transcription is turned-off (Tet-OFF). (From Sprengel and Hasan 2007). 
 
 
 
1.1.3 tTA- and rtTA-dependent Ptet/Ptetbi promoters 
  
To control the expression of a gene-of-interest, a tTA-responsive promoter, also called 
the Tet-promoter (Ptet), was engineered by linking seven Tet-operator sequences (tetO)7 
upstream to a human cytomegalovirus minimal promoter (hCMVmin) containing the 
transcription start sites with a TATA box to express gene(s) (also called Tet-responder 
genes). In addition, to simultaneously co-express two different genes, a bi-directional 
Tet-promoter (Ptetbi) was constructed by placing (tetO)7 in between two oppositely 
oriented hCMVmin (Baron et al., 1995) (Fig. 1.2). In the absence of Dox, tTA binds to 
Ptet/Ptetbi and activates gene transcription. To inactivate gene transcription, Dox binds to 
tTA, which strongly reduces the binding between tTA and tetO. Thus, in all tissues in 
vivo, gene expression can be turned “ON” and “OFF” with the tTA system by the 
removal or addition of Dox to the system respectively (Fig.1.1). 
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Figure 1.2 Schematic drawing of Ptet and Ptetbi promoters. The different promoter elements of 
the two tTA/rtTA-controlled promoters are shown. Nucleotide positions relative to the 
transcriptional start sites (position +1) are depicted (Sprengel and Hasan, 2007). 
 
 
 
However, tTA-dependent gene expression during early embryonic and postnatal 
development can interfere with cellular physiology and early development. To switch-off 
tTA-dependent gene expression prenatally, pregnant mice can be treated with Dox in 
drinking water at doses, which are appropriate for brain and non-brain tissues. Successful 
re-activation of gene expression can be achieved upon Dox removal. However, this 
procedure for gene re-activation is not without problems, especially with studies related 
to the nervous system. First, it was found that wild-type mice prenatally treated with Dox 
were impaired in fear-related associative learning and memory (Mayford et al., 1996), 
which might be related to Dox-induced toxicity in neurons during prenatal development 
(Mayford et al., 1996). Second, when gene expression was kept in the off state, by 
administering Dox during embryonic development, re-activation of tTA-dependent gene 
expression in the adult brain was very slow (several weeks to months). Interestingly, even 
after re-activation, gene expression levels in neurons were variable and gene expression 
patterns in brain slices were highly mosaic (Bejar et al., 2002, Lindeberg et al., 2002, 
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Krestel et al., 2004). The slow gene reactivation kinetics can be largely due to the slow 
Dox efflux from the brain tissues after it is absorbed in lipid tissues. However, it was very 
puzzling why gene re-activation levels were variable and gene expression patterns were 
highly mosaic. 
 
 
1.1.4 The reverse tTA (rtTA) system 
 
To overcome these difficulties, an ideal inducible system was desired that would activate 
and inactivate gene expression with Dox addition and removal, respectively. This would 
overcome the biological problems associated with Dox-controlled, tTA-dependent 
inactivation of gene expression during prenatal and early postnatal development. A 
reverse TetR (rTetR) variant was identified that was used to generate the reverse tTA 
(rtTA) system (Gossen et al., 1995). This new variant was generated by four point 
mutations in the TetR, E71K, D95N, L101S and G102D, which lead to the reversal of the 
pharmacology of TetR (Hecht et al., 1993, Gossen et al., 1995). Only when bound to Dox 
can the rtTA bind to Ptet/Ptetbi to activate gene transcription and gene expression is 
switched-off when Dox unbinds rtTA (Gossen et al., 1995). Subsequently, an improved 
rtTA variant, rtTA-M2 (Urlinger et al., 2000) was generated which, compared to the 
original rtTA , requires nearly ten-times lower Dox concentration for full gene activation 
(Gossen et al., 1995).  
Both tTA and rtTA have been successfully applied in different mouse tissues 
(Kistner et al., 1996) including the brain (Mayford et al., 1996, Mansuy et al., 1998). 
 
 
1.1.5 Improvement of the tTA/rtTA systems  
 
The original tTA/rtTA systems were equipped with the VP16 as an activation domain. It 
was found that high VP16 levels in cells have toxic side effects (Berger et al., 1992), 
largely due to ‘squelching’ which is a consequence of titrating components of the 
transcriptional machinery from their respective intracellular targets (Gill and Ptashne, 
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1988). To reduce the toxicity, a 12 amino acids minimal transcriptional activation domain 
(F-domain), incapable of interacting with various cellular transcriptions factors, was 
derived from VP16 (Fig. 1.3) (Baron et al., 1997, Kim, 2001). When compared to the 
originally described transactivator (Gossen and Bujard, 1992, Gossen et al., 1995), the 
new Tet transactivator variant with minimal activation domains was well tolerated at 
higher intracellular concentrations (Baron et al., 1997). Additionally, a nuclear 
localization signal inserted at the N-terminus of the tTA improved the binding efficiency 
of tTA to the Ptet responder in the nucleus (Urlinger et al., 2000, Hasan et al., 2001, Kim, 
2001, Krestel et al., 2004). It appears that the use of three F-domains is an optimal trade-
off for minimal cellular toxicity and robust gene activation. 
 
 
 
 
Figure 1.3 Schematic drawings for some currently available tTA and rtTA variants. The 
TetR core region with 10 α-helices (1-10) contains sites for tetO binding, Tet binding and 
homodimerization. VP16 or minimal F-domains make up the transactivation domains. The 
position of the nuclear localization domain (n) is indicated. Amino acid exchanges in different 
rtTAs are indicated by circular dots. Codon improved tTA and rtTA variants are in light grey, 
original tTA and rtTA are in black. Amino acid positions are numbered starting with the first 
amino acid (position +1). (From Sprengel and Hasan, 2007). 
 
 
 
One great advantage of the binary transcriptional systems including the tTA/rtTA system 
is that even a weak promoter driving the activator allows for expression amplification of 
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a responder gene (Iyer et al., 2004). With rAAV-tTA/rtTA systems, gene expression can 
be targeted to any brain region and neuron-types. For functional analysis of network 
activity, one could, for example use genetically encoded Ca2+ indicator proteins (FCIPS) 
(Wallace et al., 2008). By light-induced uncaging of Dox, the rAAV-rtTA system allows 
for rapid and local rtTA-dependent gene activation in neurons, even down to a single 
neuron within a microcircuit (Cambridge et al., 2009). As previously demonstrated (Zhu 
et al., 2007), the combinatorial use of transgenic tTA/rtTA-mice and Ptet/Ptetbi in rAAV 
can help to achieve cell-type specificity, and it is a versatile approach for precisely 
controlled, reversible genetic manipulation of neuronal microcircuits.  
 
 
1.2 The Tet-systems and recombinant adeno-associated viruses (rAAV) 
 
Even though the rtTA system has been explored in a variety of biological tissues, the 
performance of this system in the mammalian brain has been, with few notable 
exceptions, somewhat disappointing. Even after the construction of the improved rtTA 
variant (rtTA-M2), which has nearly 10 times higher affinity for tetO, it was still not 
possible to reliably and robustly activate gene expression with Dox in neurons. Previous 
studies showed that the rtTA system was poorly inducible in a majority of neurons in the 
postnatal mouse brain (Yu et al., 2005, Beard et al., 2006, Eckenstein et al., 2006, Uchida 
et al., 2006, Zhu et al., 2007, Zeng et al., 2008, Wortge et al., 2010). It was discovered 
that the Tet responder genes under the control of Ptet/Ptetbi introduced into the mouse 
germ-line become functionally silenced and thus unresponsive to tTA/rtTA, when kept in 
the inactive state during early development (Zhu et al., 2007). However, it was found that 
the deficiencies were overturned by the introduction of episomal recombinant adeno-
associated virus (rAAV) carrying appropriate Ptet-controlled responder genes (Zhu et al., 
2007). 
 
 
 
 
 
	   	   Introduction 
	   9	  
1.2.1 Recombinant adeno-associated viruses 
 
Adeno-associated viruses (AAV) are nonpathogenic viruses, which infect humans and 
other primates and causes very mild immune responses. The successful cloning of the 
AAV in the early 80’s enables the cloning of foreign genes into the AAV vector for 
subsequent expression in mammalian cells (Samulski et al., 1982, Laughlin et al., 1983). 
The nonpathogenic nature of the AAV makes it a very attractive tool for gene therapy. 
 
 
1.2.2 AAV genome and proteome 
 
AAV is a small (∼26 nm) replication-defective, non-enveloped virus belonging to the 
genus Dependovirus and the family of parvoviridae (Blacklow, 1988). The virus was 
initially discovered as a contaminant in adenovirus preparations (Atchison et al., 1966, 
Hoggan et al., 1966). The AAV genome is about 4.7 kb in size and is composed of 
single-stranded DNA (ssDNA), either positive- or negative-sensed (Grimm et al., 2003). 
The genome comprises inverted terminal repeat (ITRs) sequences of 145 bases at both 
ends of the DNA strand. ITRs are required for efficient multiplication of the viral genome 
and though AAV is mainly episomal, it occasionally integrates into the host genome 
using the ITR (Bohenzky et al., 1988). ITRs are required in cis- to the genes of interest, 
which replaces structural (cap) and packaging (rep) genes (Mendelson et al., 1986). The 
AAV genome consists of two major open reading frames, which encode replication (rep) 
and capside (cap) proteins (Mendelson et al., 1986).  
 There are four different Rep proteins (Rep78, Rep68, Rep52 and Rep40) 
generated from two different promoters through alternate splicing (Mendelson et al., 
1986). The Rep proteins are required for the AAV life cycle. The capsid proteins (VP1, 
VP2 and VP3) on the other hand are generated from one promoter called p40. The 
molecular weight of these capsid proteins are 87, 72 and 62 kDa respectively (Jay et al., 
1981). The capside proteins are also generated via alternate splicing and alternate start 
codon usage (Figure 1.4 A) (Mendelson et al., 1986, Trempe and Carter, 1988, Russell 
and Kay, 1999). These proteins self-organize to form a capsid of icosahedral symmetry 
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(Buning et al., 2008). The virion particle has a molecular weight of about 6.2 x 103 kDa 
(Buller and Rose, 1978, Muzyczka, 1992, Linden and Berns, 2000). 
 In order to use the AAV for more general applications, the recombinant adeno-
associated virus (rAAV) was developed by replacing the Rep and Cap genes from the 
vector with genes of interest (Fig. 1.4 B). The ITR, which is the most important viral 
component in rAAV has GC rich sequences (Fig. 1.4 C) (Russell and Kay, 1999). Also 
included in the ITR sequence are two motifs, a terminal resolution site (TRS) and a Rep 
binding site (RBS), which are necessary for replication and encapsidation of the viral 
genome. 
 
 
 
Figure 1.4 Structure of wild-type and vector AAV genomes. (A) A map of the wild-type AAV genome, 
including Rep (solid) and Cap (open) reading frames, promoters (p5, p19 and p40), polyadenylation site 
(pA), and inverted terminal repeats (ITR). The viral transcripts encoding the different Rep and Cap (VP1-3) 
proteins are shown below the genome. The smaller Rep proteins, VP2 and VP3, are translated from internal 
initiation sites. (B) Map of a typical AAV vector, showing replacement of the viral Rep and Cap genes with 
a transgene cassette (promoter, transgene cDNA, and polyadenylation site). (C) Secondary structure of the 
AAV ITR, with the locations of the Rep binding site (RBS) and terminal resolution site (TRS) indicated. 
(From Russell and Kay, 1999). 
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1.2.3 AAV serotypes 
 
As of 2008, more than 110 distinct primate AAV capsid sequences have been isolated 
(Gao et al., 2005, Schultz and Chamberlain, 2008). And there are 12 characterized 
primate serotypes (Rutledge et al., 1998, Xiao et al., 1999, Mori et al., 2004). AAVs have 
been found in many animal species, including nonhuman primates, canines, fowl, and 
humans (Xiao et al., 1999). All the characterized AAV serotypes are known to infect 
diverse tissues and cell types (Summerford and Samulski, 1998, Qing et al., 1999, 
Summerford and Samulski, 1999, Di Pasquale et al., 2003). Because the various 
serotypes infect cells via different and distinct cell surface receptors, it has been 
suggested that different serotypes will target different cell types. AAV serotype 2 
(AAV2) the most commonly used serotype is known to have tropism towards skeletal 
muscles, neurons, vascular smooth muscles and hepatocytes (Koeberl et al., 1997, 
Bartlett et al., 1998, Richter et al., 2000, Manno et al., 2003). AAV 2 uses three different 
cell surface receptors for transduction, namely heparan sulfate proteoglycan (HSPG), 
aVβ5 integrin and fibroblast growth factor receptor 1 (FGFR-1). The HSPG functions as a 
primary receptor while the other two act to enable the entry into the cell by AAV through 
receptor-mediated endocytosis (Fig. 1.7) (Summerford and Samulski, 1998, Qing et al., 
1999, Summerford et al., 1999). 
 Different AAVs have been tested in the nervous system including AAV1, AAV2, 
AAV4, AAV5, AAV6, AAV7 and AAV8 (Alisky et al., 2000, Davidson et al., 2000, 
Yang et al., 2002, Burger et al., 2004). Although AAV2 has been used predominantly, 
AAV1 and AAV5 have demonstrated higher infectivity in the CNS in regions such as 
hippocampus, striatum, globus pallidus, substantia nigra and spinal cord (Wang et al., 
1998, Alisky et al., 2000, Burger et al., 2004). However, in my PhD work, a cross-
packaging of AAV1 and AAV2 were used (Zhou and Muzyczka, 1998, Hasan et al., 
2004, Tang et al., 2009). 
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1.2.4 rAAV production and delivery system 
 
Since AAVs are replication defective viruses, they require genes of a helper virus, such 
as adenovirus or herpes virus (Hermonat and Muzyczka, 1984). Originally, adenovirus 
and herpes simplex virus were used for producing rAAVs (Hermonat and Muzyczka, 
1984, Flotte and Carter, 1995, Conway et al., 1997, Zhou and Muzyczka, 1998). 
However, for in vivo application, it is important to avoid the use of adenovirus or the 
herpes virus. To overcome this, the required helper genes E4, E2A and VA from 
adenovirus were used to construct a helper plasmid named pDG plasmids (Fig. 1.5) 
(Grimm et al., 2003). This plasmid also contains rep gene derived from AAV2 and cap 
genes from serotypes 1-6 (Grimm et al., 1998, Grimm et al., 2003). This cross-packaged 
rAAV vector plasmid and the different helper plasmids (pDG) were found to be about 10 
times more efficient than the traditional adenovirus used (Grimm et al., 1998, Grimm et 
al., 2003). 
 
 
 
 
Figure 1.5 Map of pDG plasmid. Plasmid pDG carries all essential genes for packaging of AAV-2 vectors 
into capsids of AAV-2, i.e., AAV-2 rep and cap genes and VA, E2A, and E4 genes of adenovirus 5. Five 
novel helper constructs were derived from pDG by exchanging the AAV-2 cap gene with cap of AAV 
serotype 1, 3, 4, 5, or 6 (from Grimm et al., 2003). 
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By transfecting HEK293 cells with pDG plasmids together with an AAV plasmid in a 
heterologous expression system, virus particles with high infectivity can be packaged  
(Fig. 1.6) and purified (Hermens and Verhaagen, 1998, Auricchio et al., 2001, Zolotukhin 
et al., 2002, Hauck et al., 2003, Sun et al., 2003, Zeltner et al., 2010). 
 
 
1.2.5 Cellular entry and trafficking of rAAV  
 
Entry of AAV into the cell is by the attachment of the virus to the cell surface receptor 
followed by internalization. The primary receptor for AAV2 is heparan sulfate 
proteoglycan, but it has also been found that interaction with other co-receptors is of 
importance for virus internalization (Schultz and Chamberlain, 2008). Fibroblast-growth 
factor receptor-1 and αvβ5 integrin can act as co-receptors (Qing et al., 1999, Summerford 
et al., 1999, Sanlioglu et al., 2000, Schultz and Chamberlain, 2008). There are other 
receptors for other serotypes as well, such as O-linked 2,3-sialic acid for AAV4 and N-
linked sialic acids for AAV5 (Kaludov et al., 2001, Walters et al., 2001). Internalization 
of AAV occurs through receptor-mediated endocytosis through clathrin-coated pits  (Fig. 
1.7) (Bartlett et al., 2000, Seisenberger et al., 2001).  
Once internalized, the AAV is processed in the endosome, trafficked into the 
nucleus via lysosomes and the Golgi apparatus (Fig. 1.7). Inside the nucleus, the virus is 
uncoated and forms episomal concatamers (Chen et al., 2001). In non-dividing cells, 
these concatamers remain intact throughout the life of the cell. Random integration of 
AAV DNA into the host genome is rare (McCarty et al., 2004). In dividing cells, AAVs 
are diluted by every cell division because the episomal DNA is unable to replicate in host 
cells lacking cap and rep genes. 
Another major advantage of the rAAVs is that they can target gene expression 
into selected cell types at any time in the animal’s life (During, 1997) by using cell-type 
specific promoters. That allows detailed investigation of gene function without 
interference during development, as is the case with traditional transgenic mice derived 
by pronuclear DNA microinjections (Gordon and Ruddle, 1982, Mann and McMahon, 
1993). This not only obviates the use of conditional transgenics, but also readily expands 
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the use of transgenesis to species other than rodents. With multiple viruses, it is possible 
to deliver and thus express multiple genes simultaneously, even in different spatially 
defined locations (Shevtsova et al., 2005). Co-infectivity of viral particles can be as high 
as >85 % (Shevtsova et al., 2005). Maximum transgene expression can be observed in a 
matter of weeks and typically persists throughout life (Klein et al., 2002).  
The rAAV-vectors equipped with tetracycline-dependent genetic switches have 
been engineered for inducible gene expression in the mouse nervous system (Zhu et al., 
2007). We used a two-virus approach: the first virus expresses either tTA or rtTA under 
the control of a ubiquitous or a cell-type-specific promoter. The second virus, the 
responder virus, is equipped with a Ptetbi to express at least two genes simultaneously. 
 
 
 
 
 
Figure 1.6 General scheme of rAAV2 vector production. The rAAV vectors have been constructed by 
the removal of endogenous viral genes, and the insertion of an expression cassette(s) between flanking 
ITRs. The rAAVs are generally encapsidated by transfection of a plasmid containing the rAAV vector into 
cells with provision of AAV rep and cap (as either plasmids or by using cells expressing them) and 'helper' 
virus functions such as Adenovirus E1, E2, E4, and VA RNAs (either as a plasmid or by viral infection). 
The resulting vector is then purified for use using density gradient centrifugation (CsCl2 or Iodixanol) 
and/or column purification (from Sun et al., 2003). 
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Figure 1.7 Schematic representation of cell entry and trafficking of recombinant adeno-associated 
virus (rAAV). Stages and various cellular events during AAV cell transduction. The process starts with the 
viral binding to the cell surface receptor and entry by receptor-mediated endocytosis, followed by 
trafficking to the nucleus, uncoating and viral gene expression (Schultz and Chamberlain, 2008). 
 
 
 
1.3 The Cre /loxP recombinase system 
 
Cre recombinase (Cre) is an enzyme from the P1 bacteriophage, which catalyzes site-
specific DNA recombination between loxP sites (Abremski and Hoess, 1984, Hamilton 
and Abremski, 1984, Sauer and Henderson, 1989, Nagy, 2000). The loxP site is a 34 bp 
consensus sequence, consisting of spacer sequence of 8 bp and two 13 bp palindromic 
flanking sequences (Nagy, 2000).  Recombination takes place within the spacer area of 
the loxP sites. Introduction of the Cre/loxP sites into the mammalian (eukaryotic) system 
by transgenesis serves as a powerful tool to study gene functions in a conditional 
knockout mouse model. The system is of tremendous importance to neuroscience because 
it allows for region- and cell-type specific gene knockout in the mouse brain. In the 
present study, I employed the rAAV system expressing the Cre recombinase enzyme to 
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conditionally and inducibly knockout the NMDA receptor subunit NR1 in a region 
specific manner in NR1-2lox mice (Niewoehner et al., 2007). I also used the same system 
to investigate site-specific gene recombination in the Rosa26R mice (Soriano, 1999). 
 
 
1.4 NMDA receptors in learning and memory 
 
The notion that information is stored in the brain has been with us for more than a 
century following the demonstration by Cajal that networks of neurons communicate 
with each other at specialized junctions called synapses. Neurons are therefore thought to 
communicate with each other through various neurotransmitters mediated by receptors 
(Bliss and Collingridge, 1993). One of these receptors is the N-methyl-D-aspartate 
(NMDA) receptor. The NMDA receptor is a heterotetrameric ionotropic glutamate 
receptor consisting of two obligatory NR1 and two regionally localized NR2 subunits 
(Fig. 1.8) (Monyer et al., 1992, Witt et al., 2004, Stephenson, 2006). NMDA receptors 
require the co-binding of both L-glutamate and glycine and the relief of a voltage-
dependent blockade by magnesium ions. NMDA receptor is a non-specific cation channel 
which is permeable to Na+, K+ and Ca2+.  At physiological levels, the receptor is blocked 
by Mg2+ and can be unblocked by depolarization of the postsynaptic cell (Witt et al., 
2004). 
 NMDA receptor dependent synaptic plasticity is thought to underlie some types 
of learning and memory (Bliss and Collingridge, 1993, Bannerman et al., 1995). In 
support of this argument, it has been demonstrated that hippocampal long-term 
potentiation (LTP) and spatial learning in watermaze are impaired by blocking NMDA 
receptors with D(-)-2-amino-5-phosphonovaleric acid (AP5), a selective antagonist of 
NMDA receptor (Morris et al., 1986).  
NMDA receptors have also been implicated in associative memory. An example 
is the classical conditioning of the eyeblink reflex to neutral stimulus, which is a form of 
an associative learning and is known to involve NMDA receptors in the cerebellum, 
hippocampus, neocortex, neostriatum septum and amygdala (Christian and Thompson, 
2003). It has been shown that pharmacological manipulation of NMDA receptor by 
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agonists facilitated the acquisition of the behavioral trace eyeblink condition response 
(Thompson et al., 1992, Christian and Thompson, 2003). Systemic administration of 
other noncompetitive NMDA antagonists MK801 and phencyclidine (PCP), blocked 
acquisition of trace conditioned response at doses which caused slowing of delay 
acquisition but did not impair performance of the learned conditioned response 
(Thompson and Disterhoft, 1997). The above observations point to the role of NMDA 
receptors in memory acquisition and memory retrieval.  
A mutation in one of the receptor subunits has also been reported to produce 
similar memory deficits (Sakimura et al., 1995). It has also been demonstrated in 
transgenic mice that region specific deletion of the NMDA receptor subunit NR1 in the 
dentate gyrus (DG) of the hippocampus produced behavior phenotype with impairment in 
spatial working memory but intact hippocampus-dependent reference memory 
(Niewoehner et al., 2007). It was shown in the same transgenic mice that there is a severe 
impairment of LTP in both medial and lateral perforant path input to the DG 
(Niewoehner et al., 2007). Colchicine lesion and other lesion studies of the DG of the 
hippocampus have shown severe impairment in both spatial working memory and spatial 
reference memory (O’Keefe and Nadel, 1978 , Sutherland et al., 1983, Xavier et al., 
1999, Jeltsch et al., 2001). It was also demonstrated that ablation of NMDA receptor gene 
in CA3 pyramidal cells lead to impairment in pattern completion (Nakazawa et al., 2002).  
The role of NMDA receptors in the motor cortex in acquisition and maintenance 
of associative learning and memory was therefore investigated. With the inducible 
knockout approach, we knocked out the NR1 subunit in the motor cortex and together 
with our collaboration partners, we subjected these mice to various behavioral paradigms 
such as the Skinner box test (operant conditioning), classical conditioning of vibrissae 
responses and in vivo LTP study(Thompson and Disterhoft, 1997).  
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Figure 1.8 Model of NMDA receptor activation: The integral ion channel is blocked by magnesium in a 
voltage-dependent manner. Depolarization of the neuron removes the Mg2+ block. The binding of both L-
glutamate and glycine results in the opening of the channel, allowing Na+ and Ca2+ to enter and K+ to move 
out (from Witt et al., 2004). 
 
 
 
1.5 Neurotoxins and synaptic transmission 
 
A neurotoxin is a toxin which specifically acts on nerve cells by either interacting with 
ion channels or membrane proteins. Many of these neurotoxins are naturally occurring 
and are used by some predatory organisms for defense. Examples include toxins from 
scorpions, bees and spiders. Many of these toxins act by affecting voltage dependent ion 
channels, examples include tetrodotoxin which acts on sodium channels and agitoxin on 
potassium channels (Kao and Levinson, 1986).  Bungarotoxin on the other hand binds 
irreversibly to the acetylcholine receptor at the neuromuscular junction, causing paralysis 
and respiratory failure (Chang, 1999). Botulinum neurotoxins are another group of potent 
neurotoxins produced by different strains of Clostridium botulinum and they are 
metalloproteases. Examples include botulinum toxin from Clostridium botulinum and 
tetanus toxin from Clostridium tetani. They cleave the synaptic vesicle protein 
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synaptobrevin in the case of tetanus toxin and SNAP-25 in the case of botulinum toxin 
(Schiavo et al., 1992a, Foran et al., 2003).  
 
 
1.5.1 Reversible silencing of synaptic transmission with tetanus toxin light chain  
          (TeTxLC) 
 
Tetanus toxins belong to a family of Clostridial neurotoxins (Niemann et al., 1994). In 
their native form, these toxins are produced as single chain polypeptides and 
subsequently are cleaved into two chains linked by a single disulphide bond (Fig 1.9A) 
(Schiavo et al., 1992a). The heavy chain (HC, 100 kDa) mediates neuron-selective 
binding, internalization, intraneuronal sorting and the translocation of the 50 kDa light 
chain (LC) to the cytosol (Niemann et al., 1994, Sweeney et al., 1995). This is achieved 
by the interaction of the HC with disialogangliosides in the neuronal membrane. The 
tetanus toxin light chain (TeTxLC) is a zinc endopeptidase that proteolytically cleaves the 
synaptic vesicle protein synaptobrevin 2 (VAMP2) (Schiavo et al., 1992a, Schiavo et al., 
1992b, Sweeney et al., 1995).  
The cleavage of VAMP2 (a 19 kDa protein) takes place between Gln 76 and Phe 
77 (Schiavo et al., 1992a). Synaptobrevins are part of a core complex of proteins 
involved in vesicle fusion. Some of these proteins are the N-ethylmaleimide-sensitive 
fusion protein (NSF), α-soluble NSF attachment protein (α-SNAP), and γ-SNAP 
involved in vesicle fusion processes (Sudhof, 1995, Sweeney et al., 1995). The vesicle 
proteins are collectively called v-SNAREs for vesicle membrane and t-SNAREs for 
target membrane. Synaptobrevins are considered v-SNAREs, which target vesicles to the 
plasma membrane using syntaxin and SNAP-25. (Trimble et al., 1988, Sollner et al., 
1993, Sweeney et al., 1995). The cleavage of VAMP2 by tetanus toxin light chain 
therefore results in the prevention of Ca2+-induced fusion of synaptic vesicles to the 
presynaptic membrane and, subsequently, in the suppression of evoked synaptic 
transmission (Fig. 1.9 B) (Schiavo et al., 1992a, Sudhof, 1995, Sweeney et al., 1995).  
To study reversible silencing of synaptic transmission, we have deployed the 
tetanus toxin light chain (TeTxLC) (Martin et al., 2002) under the control of the Tet-
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inducible systems. In previous studies, TeTxLC has been elegantly used to silence 
synaptic transmission in specific neuronal cell types in mice, and functional changes in 
neuronal circuits were directly correlated to changes in learning and memory and 
behavior (Sweeney et al., 1995, Yamamoto et al., 2003, Nakashiba et al., 2008). It has 
also been demonstrated that the toxin acts exclusively at the presynaptic terminal and 
does not produce any detectable morphological changes (Sweeney et al., 1995). The 
postsynaptic response was found to be normal when exogeneous glutamate was applied 
(Sweeney et al., 1995). With TeTxLC, tTA-dependent reversibility of synaptic silencing 
was observed approximately 3 weeks after Dox treatment (Yamamoto et al., 2003, 
Nakashiba et al., 2008).  
There are other systems of reversibly silencing synaptic transmission, such as the 
use of MIST (Molecules for Inactivation of Synaptic Transmission). MIST induces 
dimerization of VAMP2 and synaptophysin, leading to a blockade of synaptic 
transmission (Karpova et al., 2005). However, MIST has to be delivered 
intracerebroventricularly (ICV), a highly invasive procedure, and this might be too 
stressful for the mice in behavior studies (Karpova et al., 2005, Lerchner et al., 2007). 
Other methods include the use of membrane-tethered toxins that bind sodium channels 
but also have their own limitations (Ibanez-Tallon et al., 2004). Silencing has also been 
achieved with the transgenic expression of the allatostatin receptor in mammalian brain. 
However, expression of the allatostatin receptor results in membrane hyperpolarization 
through endogenous G-protein-coupled inward rectifier K+ channels, making firing of 
action potentials less likely (Wehr et al., 2009).  
The use of TeTxLC as a tool for reversible silencing of synaptic transmission is 
therefore more advantageous in many ways as presented above. 
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Figure 1.9 Mechanism of action of the Clostridial neurotoxin (tetanus toxin) 
(A) Tetanus toxin is produced as a single chain polypeptide  which is cleaved by protease to generate the 
100 kDa heavy chain (HC) and the 50 kDa light chain (LC) held together by a disulphide bond. (B) The HC 
mediate the translocation and endocytosis of the LC into the cytosol and into the presynaptic terminus. The 
LC then selectively cleaves VAMP2 leading to abrogation of Ca2+-evoked synaptic vesicle release of 
neurotransmitters (modified from Schiavo et al., 1992 and Yamamoto et al., 2003). 
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2. RESULTS 
 
2.1 Long-term, Dox-controlled, tTA- and rtTA-dependent regulated gene expression 
       in neurons in vitro and in vivo 
 
 
2.1.1 Dox-controlled, tTA- and rtTA-dependent regulated gene expression in vitro 
 
To test whether the rAAV-Tet (Dox) systems can be used for rapid gene activation and 
inactivation in a Dox-dependent manner, dissociated primary neurons and rat organotypic 
brain slices were co-infected with three viruses: (a) a Tet-responder virus (rAAV-Ptetbi-
fLUC/tdTOM) to express the firefly luciferase gene and a red fluorescent protein variant 
tdTomato (tdTOM) under the control of a Ptetbi promoter, (b) an activator virus (either 
rAAV-hSYN-tTA or rAAV-hSYN-rtTA) for neuron specific expression of either tTA or 
rtTA under the control of the human synapsin promoter and (c) a control reporter virus 
(rAAV-hSYN-rLUC) to express the renilla luciferase gene under a human synapsin 
promoter. rLUC allows for normalization of variability in transfection/infection 
efficiency and sample handling during luciferase activity measurements (Fig. 2.1 A). 
Organotypic slices and dissociated primary neurons were infected with virus 
cocktail for two weeks. Robust tTA- and rtTA-dependent gene activation was observed in 
organotypic slices as visualized by tdTOM fluorescence (Fig. 2.1 B). With the rtTA 
system, gene activation was observed only in the presence of Dox after forty-eight hours 
(Fig. 2.1 B, middle). To quantify gene expression, luciferase assays were performed. 
Robust gene activation was observed with both, the tTA- (150 fold) and the rtTA-systems 
(200 fold) (Fig. 2.1 C). Luciferase activity was basal without tTA or rtTA (Fig. 2.1 C, see 
asterisk) indicating minimal leakiness of Ptetbi, thus making the rAAV-Tet systems 
applicable for gene expression studies. In rtTA infected slices there was no discernible 
gene expression in the absence of Dox when visualized by fluorescence imaging or 
quantified by firefly luciferase activity measurement (Fig. 2.1 B and C). A time course of  
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Figure 2.1 Kinetics of Tet-dependent gene regulation (continued below)  
(A) Schematics of rAAV vectors for inducible gene expression studies. A virus equipped with a human 
synapsin promoter (hSYN) to express tTA or rtTA (left upper panel), a Ptetbi virus to express two different 
reporter genes encoding the firefly luciferase (fLUC) and a red fluorescent protein variant, tdTomato (left 
lower panel) and a virus equipped with an hSYN to express renilla luciferase (rLUC) (right panel). (B) 
Dox-controlled, rtTA- (left panel) and tTA- (right panel) dependent gene activation in rat organotypic 
hippocampal slices infected with rAAV-hSYN-tTA + rAAV-Ptetbi-fLUC/tdTOM and rAAV-hSYN-rtTA + 
rAAV-Ptetbi-fLUC/tdTOM, respectively. (C) Firefly luciferase activity measurements in organotypic 
hippocampal slices. The asterisk (*) shows measurements in which tTA virus was not included in the 
infection mixture.  
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Figure 2.2 Kinetics of Tet gene regulation (continued from above) 
(A) Time course of Dox-controlled, tTA- and rtTA-dependent luciferase activity in infected dissociated 
primary neurons. The cells were incubated with Dox (1 µg/ml) and harvested at different time points. 
Luciferase activities were measured from cell lysates at different time points after Dox treatment, ranging 
from 10-2880 minutes. (B) Repeated cycles of gene activation and inactivation in dissociated primary 
neurons upon Dox administration. Cells were harvested every 48 hours after Dox addition or withdrawal 
and the lysates were used for luciferase activity measurements. 
 
 
 
 Dox-induced gene activation and inactivation was performed in dissociated neurons with 
viruses that express either tTA or rtTA in combination with the firefly luciferase under 
the control of Ptetbi promoter and a virus containing a renilla luciferase construct under 
the control of a constitutive promoter, hSYN. With the rtTA and the tTA systems, gene 
activation and inactivation by Dox (1 µg/ml of medium) was maximum or minimum, 
respectively, after 48 hours (Fig. 2.2 A). Since Dox-controlled, tTA-dependent gene 
inactivation or rtTA-dependent gene activation was nearly complete after 48 hours (Fig. 
2.2 A), a 48 hour period was chosen for recording repeated cycles of Dox-controlled gene 
activation and inactivation in vitro.   
Over a period of eight days, the firefly luciferase gene was turned “ON” and 
“OFF” in a Dox-dependent manner (Fig. 2.2 B). Residual luciferase activity was 
observed at the end of an “OFF” cycle. With a left-over residual luciferase activity, the 
subsequent cycle of gene activation thus started out with a higher basal level of luciferase 
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activity. From these results, it was estimated that the firefly luciferase has a half-life of 
approximately eight hours. Therefore, with the firefly luciferase as a reporter, an 
activation time of 48 hours and an inactivation time of 72 hours would be appropriate 
choices. It should be noted, however, that the inactivation time course should be 
determined for different proteins which might differ in their respective half-lives. With 
these findings with the rAAV-Tet systems, it should be possible to study various 
biological features by controlling gene expression in a cyclic manner in vitro.  
 
 
2.1.2 Dox-controlled, tTA- and rtTA-dependent regulated gene expression in vivo 
 
As the above kinetics of Dox-induced gene expressions were done in vitro, these results 
may not be the same in vivo. Therefore in order to perform such a kinetic study in vivo, 
the first thing was to determine the optimal Dox concentration required for tTA- and 
rtTA-dependent gene activation and inactivation. To achieve this, three viruses (rAAV-
Ptetbi-fLUC/tdTOM + rAAV-hSYN-tTA/rtTA and rAAV-hSYN-rLUC) were injected 
bilaterally into the cortices and the hippocampi of 10 wild-type mice. Two weeks after 
virus injection, mice were injected with different concentrations of Dox (3, 10, 30, and 
100 µg/g body weight, n=1 per group). Two days after Dox injection, firefly luciferase 
and renilla luciferase activities were measured from brain lysates derived from virus 
infected brain regions (four sampling points per mouse).  
With the tTA system, it was observed that 10 µg/g body weight of Dox was 
sufficient to strongly reduce gene expression (Fig. 2.3 A). When this same experiment 
was repeated with the rtTA system, it was found that 30 µg/g body weight of Dox was 
sufficient for gene activation (Fig. 2.3 B). After determining the optimal Dox 
concentration for tTA- and rtTA-dependent gene activation, the next experiment was to 
determine the number of days required to complete one cycle of gene activation and 
inactivation. To achieve this goal, 10 wild-type mice were injected into the cortices and 
the hippocampi of both brain hemispheres with the three viruses (rAAV-Ptetbi-
fLUC/tdTOM + rAAV-hSYN-tTA/rtTA and rAAV-hSYN-rLUC). Two weeks after virus 
injection, a single dose of Dox (10 µg/g body weight for tTA injected mice and 30 µg/g  
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Figure 2.3 Optimal concentration of Dox for in vivo gene regulation in the mouse brain 
(A) Luciferase activities measured from mouse brain extracts infected with rAAV-Ptetbi-fLUC/tdTOM + 
rAAV-hSYN-rLUC + rAAV-hSYN-tTA and later injected with different concentrations of Dox. 10 µg/g 
body weight of Dox was sufficient for a strong reduction in tTA dependent gene activation. (B) Luciferase 
activities from brain extracts injected with rtTA virus, followed by Dox injection. 30 µg/g body weight of 
Dox was found to be sufficient to induce optimal gene activation. (C) Time course of complete cycle of 
Dox-controlled tTA-dependent gene activation and inactivation. A single i.p. injection of Dox (10 µg/g) 
showed that gene inactivation took two days and reactivation took six days. (D) Time course of complete 
cycle of rtTA-dependent gene regulation in vivo. Luciferase activities were measured from rtTA injected 
mice, which were injected with a single dose of Dox (30 µg/g body weight). It showed that a complete 
cycle of gene activation /inactivation required 8 days. 
	   	   	   Results 	  
	   27	  
body weight for rtTA injected mice) was delivered by intraperitonial injection (i.p.). Two 
mice from each group (tTA/ rtTA) were without Dox (control).  
Firefly and renilla luciferase activities were measured from brain extracts derived 
from the cortices and the hippocampi of both brain hemispheres (Fig. 2.3 C and D). The 
brain extracts were obtained from 4 different regions per mouse. It was observed with the 
tTA system that two days were required to observe robust gene inactivation by a single 
Dox injection (10 µg/g body weight) and six days for reactivation (Fig. 2.3 C). The rtTA 
system on the other hand, required two days after a single Dox (30 µg/g body weight) 
injection to observe optimal gene activation and six days for inactivation (Fig. 2.3 D). 
One could therefore conclude from these experiments that a complete cycle of Dox-
controlled tTA/rtTA-dependent gene activation and inactivation can be done in eight days 
(Fig. 2.3 C and D). 
 Based on the above results, repeated cycles of gene activation and inactivation in 
vivo were performed. To do this, 10 wild-type mice were injected with three viruses 
(rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-tTA and rAAV-hSYN-rLUC) and 10 other 
mice with the other three viruses (rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-rtTA and 
rAAV-hSYN-rLUC) into the cortices and the hippocampi of both brain hemispheres. tTA 
injected mice were all (except 2) injected with 10 µg/g body weight of Dox at different 
time points for sixteen days  (i.e  2 days of Dox injection for inactivation, followed by 6 
days of withdrawal for reactivation) (Fig. 2.4 A). Two complete cycles of gene regulation 
were achieved in 16 days. 
Mice injected with the firefly luciferase, renilla luciferase and rtTA viruses were 
also injected with 30 µg/g Dox at different time points for 16 days (2 days of Dox 
injection for activation and 6 days of Dox withdrawal for gene inactivation). At the end 
of two cycles of gene regulation, luciferase activities were measured from brain extracts 
from all virus-infected mice (Fig. 2.4 B). There was about 3-fold gene regulation in both 
the tTA and the rtTA gene expression systems. These findings were in agreement with 
previous studies using transgenic mice where a 4 fold increase in in vivo gene regulation 
was observed (Hasan et al., 2001). The results also show that the in vitro kinetics is faster 
than the in vivo. Based on these in vivo and in vitro findings, it was concluded that 
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rAAVs equipped with the tetracycline genetic switches can allow for repeated cycles of 
gene activation and inactivation in vitro and in vivo. 
 
 
 
 
 
Figure 2.4 Repeated cycles of Tet-controlled gene regulation in vivo 
(A) Dox-controlled tTA-dependent repeated cycles of gene activation and inactivation in vivo. 10 wild-type 
mice were injected with a mixture of firefly luciferase, renilla luciferase and tTA viruses. These mice were 
later injected with Dox for 2 days and withdrawn from Dox for 6 days. At the end of 2 cycles of gene 
regulation covering 16 days, luciferase activities were measured from brain extracts from the cortices and 
the hippocamppi. (B) Dox-controlled rtTA-dependent cyclic gene regulation. 10 wild-type mice were 
injected with firefly luciferase, renilla luciferase and rtTA viruses. After two cycles of gene regulation, 
covering 16 days, luciferase activities were measured from brain extracts.   
 
 
 
2.1.3 Comparison between firefly luciferase (Photinus pyralis) and the Brazilian 
         luciferase (Cratomorphus distinctus)  
 
One of the objectives of the Dox-controlled tTA/rtTA dependent gene regulation kinetic 
study is to apply it to study in vivo noninvasive bioluminescence imaging. For the in vivo 
bioluminescence imaging, it is possible to capture photons emitted in living mouse brain 
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injected with the firefly luciferase viruses using the photon capturing device called 
Intensified Charged Coupled Device (ICCD) and an image processor (Sweeney et al., 
1999). In order to achieve this, the Brazilian luciferase (Cratomorphus distinctus) which 
has been reported to be 50 times better at emitting photons than the Photinus pyralis 
(fLUC) was used. Two new constructs were therefore generated of the Brazilian 
luciferase (bLUC). The first construct is under the control of Ptetbi promoter expressing 
bLUC and Venus (a green fluorescent protein variant), named rAAV-Ptetbi-bLUC/Venus 
for inducible expression and the constitutive construct rAAV-hSYN-bLUC under the 
human synapsin promoter (Fig. 2.5 A).  
To compare the activity of bLUC and fLUC under the inducible promoter, rat 
organotypic slices were infected with rAAV-Ptetbi-bLUC/Venus + rAAV-hSYN-
tTA/rtTA + rAAV-hSYN-rLUC and rAAV-Ptetbi-fLUC/tdTOM + rAAV-hSYN-
tTA/rtTA + rAAV-hSYN-rLUC (Fig. 2.5 B). Two weeks after virus infection, rtTA 
infected slices were either treated with Dox or without (control) for forty-eight hours. 
After the Dox treatment, slices were harvested for luciferase assay (Fig. 2.5 B). With both 
the tTA and the rtTA systems, it was observed that bLUC is about 60 times better in the 
relative values of firefly luciferase activities. It was also observed that there was about a 
1000 fold in gene regulation of bLUC compared to fLUC, which was about 300 fold.  
These results confirmed that bLUC is better suited for in vivo bioluminescence imaging.  
 Based on the in vitro luciferase assay data, 5 NMRI mice were injected with 
rAAV-Ptetbi-bLUC/Venus + rAAV-hSYN-tTA + rAAV-hSYN-rLUC and 5 NMRI mice 
with rAAV-Ptetbi-bLUC/Venus + rAAV-hSYN-rtTA + rAAV-hSYN-rLUC (NMRI mice 
were used for the in vivo bioluminescence imaging because their white fur, allow more 
photons to pass through than the C57BL/6). These viruses were injected into the medial 
parietal associative cortex (Fig. 2.5 C, pink arrow) and the constitutive rAAV-hSYN-
bLUC was injected to the motor cortex (Fig. 2.5 C, white arrow). The extent of virus 
infection is indicated with the Venus expression, which is about 1.5 mm in diameter. The 
two coordinates were chosen to be far apart to allow for the separation of the photons 
coming from the inducible expression and the constitutive expression. The inducible 
expression system should exhibit an “ON/OFF” cycles of gene regulation by the 
observation of photons, which should disappear/appear on Dox injection or withdrawal.  
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Figure 2.5 Brazilian luciferase (Cratomorphus distinctus) and firefly luciferase activities in vitro  
(A) Schematics of the Brazilian luciferase (bLUC) constructs under the Ptetbi promoter (left) and under the 
constitutive human synapsin promoter. (B) Organotypic slice infected with rAAV-Ptetbi-bLUC/Venus + 
rAAV-hSYN-tTA (left). Firefly luciferase activity measurements from organotypic slices infected with 
rAAV-Ptetbi-bLUC/Venus + rAAV-hSYN-tTA/rtTA + rAAV-hSYN-rLUC and rAAV-Ptetbi-fLUC/tdTOM 
+ rAAV-hSYN-tTA/rtTA + rAAV-hSYN-rLUC. The findings indicate that bLUC is better regulated and 
shows higher luciferase expression compared to fLUC. (C) In vivo expression of rAAV-Ptetbi-bLUC/Venus 
+ rAAV-hSYN-tTA (pink arrow) injected into the medial parietal associative cortex and the constitutive 
rAAV-hSYN-bLUC (white arrow) injected to the motor cortex. Right panel is a coronal section of the viral 
injected site expressing the inducible rAAV-Ptetbi-bLUC/Venus. 
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However, the constitutive bLUC should be “ON” throughout the investigation.  
 
 
2.2 Inducible, subregion- and cell-type restricted gene expression and gene knockout 
      in the mouse brain 
 
To investigate whether Tet-inducible gene expression can be achieved in vivo in the 
mouse brain, different brain regions of wild-type mice were injected with a mixture of 
activator (rAAV-hSYN-rtTA) and responder (rAAV-Ptetbi-iCre/tdTOM) viruses (Fig. 2.6 
A) (Zhu et al., 2007). To test the virus for expression, six rat hippocampal organotypic 
slices were infected with the two viral cocktail (rAAV-hSYN-rtTA and rAAV-Ptetbi-
iCre/tdTOM). Two weeks after virus infection, four slices were incubated with 1 µg/ml 
Dox in the medium for 48 hours while the remaining two were without Dox (control). 
Robust gene activation was observed in all Dox treated slices after forty-eight hours (Fig. 
2.6 B, right panel). Slices without Dox showed undetectable expression of tdTOM (Fig. 
2.6 B, left panel), indicating that the system is tight and leakiness is minimal.  
 After the in vitro experiment with organotypic slices, viruses (rAAV-hSYN-rtTA 
and rAAV-Ptetbi-iCre/tdTOM) were injected stereotaxically into different brain regions of 
wild-type mice (cortex, the hippocampus or both). In total, eight mice were injected (two 
were injected into only hippocampus, two into the cortex and four into both cortex and 
the hippocampus). Two weeks after virus injection, six mice were injected with a single 
dose of Dox (100 µg/g body weight), the remaining two served as a control (without 
Dox). Two days after Dox injection, mice were perfused and 100 µm thick coronal slices 
were imaged for gene expression. Dox injected mice showed robust gene expression in 
virus-infected areas of the brain (Fig. 2.6 C, upper and lower panels). The viral spread 
was about 0.5-1.5 mm in diameter. Layer 2, 3 and 5 of the cortical pyramidal neurons 
were massively infected by the rAAV with the soma and dendrites showing strong 
expression while layer 4 and 6 neurons were largely spared of infection. This 
phenomenon has been observed in all instances of virus injection into the cortex (Fig. 2.6 
C and Fig. 2.8 A). Granule cells of the dentate gyrus and CA1 pyramidal neurons were  
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Figure 2.6 Dox-induced, rtTA-dependent brain region- and cell type-specific gene activation in vivo 
(A) Schematics of rAAV-rtTA system, a virus with a human synapsin promoter for constitutive rtTA 
expression and a second virus containing Ptetbi to express two different genes, the Cre recombinase and a 
red fluorescent protein variant, tdTOM. Binding of Dox to rtTA enables the rtTA to bind to Ptetbi, thus 
activating gene expression. (B) Rat organotypic slices were infected with rAAV-hSYN-rtTA and rAAV-
Ptetbi-iCre/tdTOM and gene expression was imaged in the absence and presence of Dox. (C) Fluorescent 
images of 100 µm thick coronal sections from mouse brain infected with rAAV-hSYN-rtTA and rAAV-
Ptetbi-iCre/tdTOM. Gene expression was imaged in the absence and presence of Dox. Abbreviations: 
hippocampus (HP), cortex (Ctx), layer (L). (D) Time course of Dox-induced gene activation in vivo. 
Images of wild-type mice injected with rAAV-hSYN-rtTA + rAAV-Ptetbi-iCre/tdTOM into the cortex, 
followed by Dox injection at different time points over 2 days. 
	   	   	   Results 	  
	   33	  
 also robustly infected including the mossy fibers (Fig. 2.6 C). Dox untreated mice 
showed basal expression, indicating marginal leakiness (Fig. 2.6 C, left).  
To investigate the time course of Dox-controlled, rtTA dependent gene activation 
in vivo, viruses (rAAV-hSYN-rtTA and rAAV-Ptetbi-iCre/tdTOM) were injected into the 
cortex of 10 wild-type mice. Two weeks after virus infection, mice were put into five 
groups (two mice per group). The first group was without Dox but only viruses (control), 
while the other four groups were injected with Dox (100 µg/g body weight) at different 
time points (6-48 hours). After Dox injection, gene activation was monitored by 
fluorescence imaging of tdTOM (Fig. 2.6 D). Mice injected with viruses but without Dox 
showed no observable tdTOM expression (Fig. 2.6 D, left panel). On the other hand, 
mice injected with both virus and Dox showed robust tdTOM expression. Expression of 
tdTOM was observed as early as six hours after Dox injection (Fig. 2.6 D, left). The 
expression of tdTOM increases with time, reaching maximum at 24 hours after Dox 
injection and remained stable after 48 hours.  
 After demonstrating Dox-induced, rtTA-dependent gene activation in vivo, and 
also demonstrating region specific gene induction, the same system was applied to test 
for Cre/loxP-mediated gene recombination in specific brain regions in the Rosa26R mice 
(Fig. 2.7 A and B) (Soriano, 1999). Different brain regions (either cortex, hippocampus, 
or both) of eight Rosa26R mice were injected with a mixture of two viruses: (rAAV-
hSYN-rtTA and rAAV-Ptetbi-iCre/tdTOM). Two weeks after virus injection, six mice 
were injected with a single dose of Dox (100 µg/g body weight) via intraperitonial 
injection (i.p.) while the remaining two were without Dox (control). Forty-eight hours 
after Dox injection, all mice including the control were sacrificed. Coronal sections (100 
µm thick) were stained for β-galactosidase activity (LacZ staining) (Fig. 2.7 B). Cre/loxP 
gene recombination was observed in virus and Dox injected mice indicating the 
expression of the Cre enzyme. However, in the control group of mice (without Dox), 
expression was at basal level (Fig. 2.7 B, left panel). This could be due to the low basal 
activity of the Ptetbi. With multiple viruses infecting each neuron, low basal activity by 
Ptetbi also accumulates. The basal Ptetbi activity could also be due to the viral ITR, which 
act as an enhancer (Hatfield and Hearing, 1991).  
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Figure 2.7 Region-specific gene recombination: Dox-induced Cre-mediated gene recombination in 
Rosa26R mice 
(A) Schematics of Dox-controlled, rtTA-dependent Cre gene expression (left panel) and Cre-mediated gene 
recombination (right panel). (B) rAAV-hSYN-rtTA + rAAV-Ptetbi-iCre/tdTOM were injected into specific 
brain regions (cortex, hippocampus or both) of Rosa26R reporter mice and either treated with Dox or left 
untreated. β-galactosidase staining was used to monitor Cre-mediated gene recombination. 
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In order to reduce the level of leakiness due to the responder, the responder virus (rAAV-
Ptetbi-iCre/tdTOM) stock was diluted by 1:1 and 3:1 with respect to the activator virus. 
The diluted responder virus was injected together with hSYN-Venus into cortical brain 
regions of Rosa26R mice. The infectious titer determined in dissociated primary neurons 
was found to be 5 x108 transducing units per milliliter. With a 1:1 and 3:1 dilution of 
activator to Tet-responder, leakiness was reduced to undetectable levels when 
investigated by fluorescence imaging of tdTOM (-Dox, Fig. 2.8 A). Interestingly, with an 
activator-to Tet-responder dilution of 3:1, it was observed that infection was primarily 
restricted to layer 5 cortical neurons (Fig. 2.8 A, right panel). However, the constitutively 
expressed Venus also included in the same virus cocktail showed strong expression in 
both layer 2/3 and layer 5 cortical neurons (Fig. 2.8 A). This is an indication that the 
targeting/expression of the Tet-responder virus is high in layer 5 cortical neurons (Fig. 
2.8 A). When alternate slides from the same virus injected Rosa26R mice were stained 
for Cre recombinase activity by β-galactosidase staining, the leakiness was reduced 
significantly in the 3:1 dilution of the responder compared to the undiluted responder 
virus in the absence of Dox (Fig. 2.8 B, -Dox). The advantage provided by this 
experiment is that it is possible to precisely target layer specific neurons to investigate 
cortical circuitry.  
 
 
2.2.1 Region-specific Dox-mediated rtTA-dependent gene knockout in NR1-2lox 
          mice 
 
The NMDA receptor 1 gene (NR1) was chosen to investigate the role of the NMDA 
receptor in cortical map plasticity and fear-related learning and memory. Based on the 
result of the Cre-virus titration, Dox-dependent gene knockout in NR1-2lox mice was 
performed. The barrel cortex of six NR1-2lox mice (3 months old) was infected with 
rAAV-hSYN-rtTA and rAAV-Ptetbi-iCre/tdTOM for 2-3 weeks. To precisely register the 
time point of Dox delivery, four mice were treated with Dox by a single i.p. injection and 
also continuously treated with Dox in the drinking water for 1 week. Two virus infected 
NR1-2lox mice were not treated with Dox (control). The extent of virus infection in the  
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Figure 2.8 Titrating Tet responder viruses to reduce leaky expression 
(A) rAAV-hSYN-rtTA, rAAV-Ptetbi-iCre/tdTOM and rAAV-hSYN-Venus were injected into the brain of 
Rosa26R mice. Two weeks after virus injection, Dox-controlled expression was visualized by tdTOM, with 
rtTA to Tet-responder virus ratio of 1:1 and 3:1. The lower panel is a constitutive Venus expression. (B) ß-
galactosidase activity reports Cre/loxP recombination under conditions as in (A). 
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cortex was observed by tdTOM fluorescence. Without Dox, tdTOM-fluorescence was 
undetectable (Fig. 2.9 A, left panel). In Dox treated mice, gene expression was largely 
restricted to cortical layer 2/3 and 5 with layer 4 neurons largely uninfected (Fig. 2.9 A, 
right panel). Immunostaining with mouse monoclonal Cre-specific antibody revealed 
same layer specific expression (Fig. 2.9 B).  
Electrophysiological recordings were performed with 300 µm thick coronal 
cortical acute slices of layer 2/3 pyramidal neurons of the barrel cortex. Spontaneous 
NMDA-mediated miniature excitatory postsynaptic currents (NMDA-mEPSCs) were 
normal in brain slices derived from wild type and virus-infected NR1-2lox mice (without 
Dox) (Fig. 2.9 C). Virus-infected NR1-2lox mice (with Dox, 1 week) showed strongly 
reduced NMDA-mEPSCs. Additionally, an NMDA receptor specific antagonist (2-
amino-5-phosphonopentanoic acid, APV) strongly reduced charge transfer in control 
brain slices (Fig. 2.9 C), but there was virtually no further decrease in NR1 knockout 
slices. These results provide strong support for complete NR-1 gene knockout in the 
barrel cortex. 
 
 
2.2.2 Improving rAAV gene expression by co-injection with D-mannitol 
 
One limitation of the rAAV gene delivery system is that of expression. In order to 
improve the expression of the rAAV gene delivery system in vivo, a new viral delivery 
protocol was adopted. In this approach, the virus cocktail was mixed with 20-25 % D-
mannitol in 0.9 % NaCl. D-mannitol is a simple monosaccharide derived from fructose. It 
is generally used as osmotic diuretic agent, which causes temporal relaxation of the blood 
brain barrier (Mastakov et al., 2001, Carty et al., 2010). To enhance virus delivery with 
this method, rAAV-Ptetbi-iCre/tdTOM + rAAV-hSYN-rtTA were injected into the motor 
cortex of eight C57BL6 wild-type mice under different conditions (Fig. 2.10). The eight 
mice were put into four different groups (two mice per group). The first group was 
injected with 300 nl of virus only (Fig. 2.10, far left), the second group had intraperitonial 
injection of D-mannitol (3 ml of sterile 25 % mannitol in 0.9 % saline per 100 g body 
weight) (Louboutin et al., 2010) at least 20 minute prior to 300 nl of only virus injection  
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(Fig 2.10, middle left). The third group was injected with a mixture of virus (150 nl) and 
D-mannitol (150 nl). Meaning in this case, the volume of virus particle is half that of 
groups one and two (Fig. 2.10, middle right).  
 
 
 
 
 
Figure 2.9 Inducible knockout of the NMDA receptor 1 gene  
 (A) Tet-inducible Cre-viruses delivered to the barrel cortex of NR1-2lox mice. Mice were either Dox-
treated (1 week) or left untreated. Expression was visualized by tdTOM fluorescence imaging. (B) Mouse 
monoclonal anti-cre-immunostaining (primary antibody) followed by FITC secondary antibody in Dox-
treated NR1-2lox mice. (C) Spontaneous NMDA-mediated miniature excitatory postsynaptic currents in 
acute brain slices of wild type (WT) and viruses/NR1-2lox treated with or without Dox (1 week). An 
NMDA receptor specific antagonist (APV) was used to blocked NMDA-mediated charge transfer. 
Abbreviation: n= number of mice or cells. 
 
	   	   	   Results 	  
	   39	  
The last group was injected with D-mannitol by i.p. and a 1:1 mixture of virus and D-
mannitol (Fig. 2.10, far right). Two weeks after virus injection, all mice were injected 
with 100 µg/g body weight of Dox and after 48 hours, mice were analyzed for tdTOM 
expression pattern. It was observed from this experiment that the virus infection was 
mainly in layer 5 in the first group of mice analyzed and the spread was about 0.9 mm in 
diameter, while in the second group, infection was observable in almost all layers (layer 
2/3, layer 4 and layer 5) and the spread was about 1 mm in diameter. In the third group of 
mice, infection was mainly in layer 2/3 and layer 5, however, virus spread was about 0.8 
mm. In the last group, despite the fact that the actual volume of virus delivered was half 
of group 1 and group 2, the virus spread was the largest observed, covering about 2 mm 
in diameter. This observation confirmed an earlier observation (Betz et al., 1998). These 
findings therefore indicate that prior i.p. injection of D-mannitol and a combination of 
virus D-mannitol mixture vastly improve virus delivery by increasing the number of 
neurons infected in vivo and also widening the virus spread (Fig. 2.10). NeuN staining on 
same slides indicates virus infected cells were mainly neurons (Fig. 2.10, lower panels). 
 
 
2.2.3 The role of NMDA receptors in the motor cortex in associative learning and 
          memory  
 
To investigate the role of NMDA receptors in the motor cortex in associative learning 
and memory, 20 NR1-2lox mice and 20 wild-type mice were injected into the motor 
cortex at 6 different spots with rAAV-Ptetbi-iCre/tdTOM + hSYN-rtTA (Fig. 2.11 B). The 
motor cortex covers about 3 mm of the mouse’s forebrain and the diameter ranges from 
05-1.5 mm (Fig. 2.10 A). To ensure that the virus spreads across more than 70 % of this 
region, the injection was done using the mannitol protocol described above (Fig. 2.10, far 
right). 	  
The mice were later put on Dox for three weeks to enable expression of the Cre 
gene and the deletion of the NMDA receptor 1 gene (from the previous experiment, we 
were able to delete the NMDA receptor within a week after placing the mice on Dox 
(Fig. 2.9 C). Figure 2.11 B showed an overview of the virus injections (white arrows). 
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This indicates that the virus spread covers more than 2 mm of the motor cortex. 100 µm 
coronal sections from a representative mouse brain indicate that the lateral spread of the  
 
 
 
 
 
Figure 2.10 Effect of D-mannitol on in vivo virus expression pattern 
Wild-type mice infected with rAAV-Ptetbi-iCre/tdTOM + hSYN-rtTA with or without D-mannitol in the 
motor cortex. The first group of mice was injected with virus only (300 nl). The observed virus spread was 
mainly in layer 5 and about 0.9 mm wide. In the second group (second image from left) mice were injected 
with viruses and i.p injection of D-mannitol. Virus spread mainly in all layers and the spread is about 1mm. 
In the third group, (3rd image from left), mice were injected with virus and mannitol mixture (1:1). Infection 
was mainly in layer 2/3 and 5 and the viral spread was 0.8 mm. In the last group, mice were injected with 
virus/mannitol mixture (1:1), and i.p. mannitol: Infection was mainly in layer 2/3 and 5. This group also 
showed the widest virus spread of about 2 mm. NeuN staining also indicated more neurons are labeled in 
the last group. 
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virus is 1mm or more in diameter (Fig 2.11 C and D). It was observed that more than 70 
% of the motor cortex expressed the viruses. Cell counts using confocal images of 100 
µm coronal sections indicated that within the infected regions, more than 90 % of NeuN 
positive cells expressed tdTOM. Viral infection was observed in layer 2/3 and 5 
excluding layer 4. Immunostaining with mouse monoclonal Cre antibody showed that 
most (> 80 %) of all tdTOM positive neurons were also Cre positive (Fig. 2.11 E). This 
implies that the Ptetbi promoter drove the expression of both genes, to nearly equal extent. 
The wild-type mice and the NR1-2lox mice injected with the viruses are currently being 
analyzed to assess the role of the motor cortex NMDA receptors in associative learning 
and memory.  
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Figure 2.11 Viral mediated Cre expression in the motor cortex.  
(A) An overview of the mouse brain showing the dimension of the motor cortex indicated by the pink bar 
(from Paxinos and Franklin, 2001). (B) An overview of the adult mouse brain injected with rAAV-Ptetbi-
iCre/tdTOM + rAAV-hSYN-rtTA into the motor cortex followed by one week of Dox treatment. (C) 100 
µm coronal sections expressing tdTOM (left) and immunostained with mouse anti NeuN primary antibody 
and an FITC coupled secondary antibody (right) arranged in a chronological order from the forebrain to the 
midbrain (D) Confocal images of tdTOM expressing regions overlaid with FITC NeuN immunostained 
regions indicate that all tdTOM expressing cells are neurons. The lower panel is a higher magnification of 
the highlighted region (rectangular box) showing a near 100 % overlay of tdTOM and NeuN. (E) 
Immunostaining with mouse monoclonal anti-Cre antibody followed by FITC secondary antibody indicates 
that most tdTOM positive cells are also Cre positive. 
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2.3 Inducible and reversible silencing of synaptic transmission with tetanus toxin 
       light chain (TeTxLC)  
 
In order to dissect the role of different neuron types in circuit function, the tetanus toxin 
light chain (TeTxLC) gene was placed under the control of rAAV-tTA/rtTA systems for 
inducible and reversible silencing of synaptic transmission (Fig. 2.12 A). TeTxLC is 
known to selectively cleave the synaptic vesicle protein synaptobrevin-2 (VAMP2) (Fig. 
1.9) (Schiavo et al., 1992a, Yamamoto et al., 2003). To detect TeTxLC expression, rAAV 
equipped with a human synapsin promoter was used to express the TeTxLC gene that 
was linked to the monomeric kusabira orange (mKO) via a 2A peptide (Tang et al., 
2009). The rAAV from this construct (TeTxLC-2A-mKO), was used to infect four rat 
organotypic hippocampal slices for two weeks. Strong expression of mKO was detected 
by fluorescence imaging in infected slices (Fig. 2.12 B, top-left). A protein with an 
apparent molecular weight of 55 kDa that matches the molecular weight of the TeTxLC-
2A fusion protein was detected by Western blot analysis using a 2A-specific antibody 
(rabbit polyclonal) (Fig. 2.12 B, top-right).  
To confirm the in vivo expression of TeTxLC-2A fusion proteins by 
immunostaining with a 2A-specific antibody, the rAAV-hSYN-TeTxLC-2A-mKO was 
injected into wild-type mice into the CA1 region of the hippocampus. Immunostaining 
two weeks after virus infection with the 2A antibody in acute brain slices correlated well 
with mKO expression (Fig. 2.12 B, lower panels). To demonstrate that TeTxLC cleaves 
synaptobrevin-2 (VAMP2), tissue lysates from TeTxLC- infected organotypic slices were 
analyzed by Western blot for the expression of different synaptic vesicle proteins: 
VAMP1 (rabbit polyclonal), VAMP2 (rabbit polyclonal), synaptophysin (goat 
polyclonal), synaptotagmin (goat polyclonal) and cellubrevin (rabbit polyclonal). β-
tubulin (mouse monoclonal) served as a loading control. As expected, TeTxLC-infected 
slices showed strong reduction in the expression of the 19 kDa synaptobrevin-2 protein 
levels, without detectable changes in the levels of the other synaptic vesicle proteins (Fig. 
2.12 C). Surprisingly, the 15 kDa VAMP1 protein was equally undetectable in TeTxLC 
infected slices. These results showed that TeTxLC selectively cleaves VAMP2 and also 
has an impact on VAMP1 (Fig. 2.12 C).  
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Figure 2.12 Detecting TeTxLC expression 
(A) Schematics of TeTxLC expression under control of the Tet-inducible system. TeTxLC cleaves 
synaptobrevin-2. (B) Rat organotypic hippocampal slices were infected with rAAV-hSYN-TeTxLC-2A-
mKO and analyzed for the expression of a monomeric orange fluorescent protein (mKO) (top-left). The 
TeTxLC protein was detected by Western blot using a rabbit polyclonal 2A-specific antibody (top-right). 
Coronal sections from brain slices infected with rAAV-hSYN-TeTxLC-2A-mKO were immunostained 
with 2A antibody coupled to FITC secondary antibody and fluorescently imaged for mKO and TeTxLC-2A 
expression. (C) Rat organotypic hippocampal slices were infected with rAAV-hSYN-tTA and rAAV-Ptetbi-
TeTxLC/tdTOM and lysates were blotted using antibodies against different synaptic vesicle proteins: rabbit 
polyclonal antibodies against VAMP1, VAMP2 and cellubrevin, goat polyclonal antibodies against 
synaptophysin and synaptotagmin. β-tubulin (mouse monoclonal) served as a loading control.  
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2.3.1 Silencing of synaptic transmission with TeTxLC in acute hippocampal slices 
 
To provide electrophysiological evidence that TeTxLC can silence synaptic transmission 
in vivo, six wild-type mice were infected with viruses (rAAV-hSYN-tTA and rAAV-
Ptetbi-TeTxLC/tdTOM) by stereotaxic injection into the hippocampus CA3 region. 
Robust tdTOM expressions were observed in CA3 pyramidal neurons and in the mossy 
fibers two weeks after virus injection (Fig. 2.13 B). Electrophysiological recordings were 
performed on virus-infected slices with tdTOM expression serving as a guide. The 
stimulation was done in the stratum granulosum (SG) of the dentate gyrus (GD) and the 
recording at stratum lucidum of CA3 (Fig. 2.13 A). Six virus-infected and seven un-
infected wild-type mice were used for field-post synaptic potential recordings (f-PSP).  
The red fluorescent protein (tdTOM) indicates the extent of viral infection in the 
hippocampus (Fig. 2.13 B). Infection was observed widely in the CA3 pyramidal neurons 
(Fig 2.13 B, insert) and also in the mossy fibers of the DG. In a single trial, field 
postsynaptic potentials (f-PSP) were strongly reduced in TeTxLC-infected slices 
compared to non-infected slices (Fig. 2.13 C, left panel). In response to increasing 
stimulation intensities, the f-PSP slopes remained strongly reduced in TeTxLC infected 
slices compared to uninfected slices (Fig. 2.13 C, right panel). These results clearly 
demonstrate that TeTxLC blocked synaptic vesicle release by cleaving VAMP2 and 
therefore silenced synaptic transmission. It was also observed that the postsynaptic 
response remained intact when exogenous glutamate was applied into the recording 
chamber (data not shown). This is a confirmation that the action of TeTxLC is 
presynaptic and that the cells are viable. 
 
 
 
 
 
 
 
 
	   	   	   Results 	  
	   47	  
 
 
Figure 2.13 Silencing of synaptic transmission in acute brain slices 
(A) A diagram of the electrophysiological recording arrangement. The stimulating electrode was placed in 
the stratum granulosum of dentate gyrus (SG-DG) and recording electrode in the stratum lucidum of CA3 
(SL-CA3). (B) Sample image of tdTOM fluorescence expression in a hippocampal slice of a mouse 
infected with rAAV-hSYN-tTA and rAAV-Ptetbi-TeTxLC/tdTOM. Infection was robust in the CA3 
pyramidal neurons (insert) and also in the mossy fibers. (C) A single trial field potential from control  
(upper left column) and TeTxLC-infected slices (lower left panel). Plot of field potential slope with 
increasing stimulation intensities in uninfected (black trace) and in virus-infected slices (red trace). 
Abbreviations: n= number of mice, f-PSP= field postsynaptic potential. 
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2.3.2 Mice constitutively expressing TeTxLC in the striatum show ipsilateral rotatio- 
         n behavior in open field and contralateral behavior in tail suspension test 
 
To find out whether synaptic silencing could alter behavior in mice, the nigro-striatal 
pathway was chosen as a model system to investigate locomotor behavior. This pathway 
plays a crucial role in relaying dopaminergic signals from the substantia nigra to the 
motor and sensory neurons. Unilateral disruption of this pathway is known to affect 
motor coordination (Schwarcz et al., 1979, Lerchner et al., 2007). However, the effect of 
this disruption is subtle and difficult to quantify. To overcome this limitation, a previous 
study used amphetamine to boost motor activity in mice, and demonstrated that 
unilaterally virus-infected mice in the striatum rotated ipsilaterally (Schwarcz et al., 1979, 
Lerchner et al., 2007).  
To demonstrate this behavior test with TeTxLC, a constitutively expressed rAAV-
hSYN-TeTxLC-2A-mKO was injected into the striatum of wild-type mice (10) for two 
weeks. As a control, rAAV-hSYN-Venus was also injected into the striatum of wild-type 
mice (five). To assess rotational behavior, all infected mice were injected with a single 
intraperitonial dose of amphetamine (5 mg/kg) and placed in a square open-field box (50 
cm x 50 cm) for 10 minutes. The locomotor activity with and without amphetamine 
treatment (Fig. 2.14 A, upper-left) was video-recorded (Movies M2A and B). A mouse is 
considered to have made one rotation if it turned round in a circle, turns made circling the 
periphery of the box were not counted as rotation scores (M 1B and M 2B). Post-hoc 
analysis of both TeTxLC-2A-mKO and Venus injected mice indicate expression of mKO 
and Venus in the striatum respectively and also no visible damage to tissues in the 
striatum as a result of the virus injection (Fig. 2.14 A, right panel). These mice (rAAV-
hSYN-TeTxLC-2A-mKO) in a tail suspension test (TST) also displayed preferential 
turning into the contralateral direction to the virus-infected hemisphere (Fig. 2.14 B, M 
4). TST is one of the most common tests used to access antidepressant-like activity in 
mice (Cryan et al., 2005). This test takes advantage of the fact that animals subjected to 
short-term inescapable tail suspension will develop an immobile posture (Cryan et al., 
2005). In this test, virus-injected mice were suspended by the tail for one minute. 
TeTxLC-2A infected mice turned to the right direction (injected into the left hemisphere). 
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Figure 2.14 rAAV-hSYN-TeTxLC-2A-mKO produced behavioral phenotypes  
(A) rAAV-hSYN-TeTXLC-2A-mKO was injected into the striatum followed by amphetamine induce 
rotational behavior studies. Virus injected mice displayed ipsilateral rotational behavior. Post-hoc analysis 
of the injected hemisphere showed expression of mKO. (B) In a tail suspension test, mice injected with 
rAAV-hSYN-TeTXLC-2A-mKO into the left hemisphere turned contralaterally to the injected brain 
hemisphere while the control mice had no special preference to any side. Post-hoc analysis of the control 
(rAAV-hSYN-Venus injected mice) indicated broad infection in the striatum. (C) Western blot analysis 
with antibodies against VAMP1, VAMP2 and β-tubulin indicated the TeTxLC cleaves both VAMP1 and 
VAMP2. 
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Venus injected control on the other hand displayed no preferential direction (Fig. 2.14 B, 
M 4). To demonstrate that the TeTxLC-2A-mKO also cleaves VAMP1 and VAMP2, rat 
organotypic slices were infected for two weeks and the tissues were harvested and lysed 
for Western blot with antibodies against VAMP1 and VAMP2 (Fig. 2.14 C). From the 
Western bIot data, it was observed that the bands corresponding to both VAMP1 and 
VAMP2 in the infected slices disappeared (Fig. 2.14 C). This result clearly demonstrates 
that the constitutively expressed TeTxLC also cleaves its target proteins.   
 
 
2.3.3 tTA- and rtTA-dependent reversible silencing of synaptic transmission in  
         freely behaving mice 
 
To investigate reversible silencing of synaptic transmission, rAAV-hSYN-tTA and 
rAAV-Ptetbi-TeTxLC/tdTOM were injected unilaterally into the striatum of four wild-
type mice (Fig. 2.15 A, lower left). For a control, three wild-type mice were also injected 
with rAAV-hSYN-Venus into the striatum. To assess rotational behavior, all infected 
mice were injected with a single intraperitonial dose of amphetamine (5 mg/kg) and 
placed in a square open-field box (50 cm x 50 cm) for 10 minutes. The locomotor activity 
with and without amphetamine treatment (Fig. 2.15 A, upper-right) was video-recorded 
and the number of 3600 cycles completed by the mice were manually counted (Movies M 
2 A and B). After amphetamine injection, the total number of ipsilateral rotational cycles 
completed by mice injected with the TeTxLC-virus was 350 in 10 min (35 
rotations/minute) (Fig. 2.15 B). To ruled-out the effect of viral injection as being the 
cause of the observed rotation, rAAV-hSYN-Venus was injected as a control into three 
wild type mice (Fig. 2.15 A, top-left). In the control mice, amphetamine injection resulted 
in a large increase in motor activity with rapid movements around the four corners of the 
field, but 3600 rotational behavior was not observed (Fig. 2.15 A, right, M 1A and B). 
The TeTxLC infected mice upon amphetamine injection turn to explore little space in the 
open field box compared to the Venus injected mice.   
To switch-off TeTxLC expression, the infected mice were treated with 2 mg/ml 
Dox in their drinking water supplemented with 5 % sucrose. Amphetamine-induced 
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rotational behavior was recorded over the period of Dox treatment, which lasted for 12 
weeks. It was observed that the rotation scores decreased but very gradually, reaching 
half the initial value after 5 weeks of Dox treatment (Fig. 2.15). The rotation score 
reached basal level and plateau after more than 8 weeks of being put on Dox. The 
rotation score was about 50 per 10 min (5 rotations /min) (about 5-fold decrease) in 10 
weeks, which is consistent with previously published data (Lerchner et al., 2007, Auer et 
al., 2010). However, complete reversal of rotation was not achieved (Fig. 2.15 B). This is 
in conformity with previous findings (Lerchner et al., 2007). However, the mice return to 
almost the maximum observed rotation score when Dox was withdrawn for one week 
(Fig. 2.15 B, week 11). Post-mortem analysis of Dox-treated TeTxLC-injected mice 
showed that gene expression was indeed switched-off as judged by the absence of 
tdTOM expression in the infected striatum (Fig. 2.15 C, left panel). Also there was no 
observed morphological damage to structures in the striatum of both control and TeTxLC 
infected mice. This could be an indication that the neurons of the striatum remained 
active and functional, however, this need to be confirm with apoptosis markers. Because 
the TeTxLC protein has a long half-life (6 days), it was most likely that the TeTxLC was 
not completely depleted and this might have accounted for the low rotation observed 
even after 10 weeks of Dox treatment.  
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Figure 2.15 Amphetamine-induced rotational behavior-test upon unilateral silencing of synaptic 
transmission in the striatum 
(A) Mice unilaterally infected with viruses into the striatum: rAAV-hSYN-Venus (upper left panel) and 
rAAV-hSYN-tTA + rAAV-Ptetbi-TeTxLC/tdTOM (lower left panel). Ten minutes of locomotor activity 
trace in the open field without (middle panel) and with (right panel) amphetamine. (B) Mice infected with 
rAAV-hSYN-tTA and rAAV-Ptetbi-TeTxLC/tdTOM were put on Dox in the drinking water (2 mg/ml) for 
up to 12 weeks and rotational scores were determined. (C) Post-mortem analyses of rAAV-hSYN-tTA and 
rAAV-Ptetbi-TeTxLC/tdTOM mice on Dox (left) and rAAV-hSYN-Venus infected mice as a control 
(right). 
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2.3.4 Dox-controlled, rtTA-dependent TeTxLC expression induces rotational 
         behavior 
 
To test the rtTA system for rapid expression of TeTxLC, rat hippocampal organotypic 
slices were infected with rAAV-hSYN-rtTA and rAAV-Ptetbi-TeTxLC/tdTOM. Two 
weeks after virus infection, when stimulating the mossy fiber pathway (Fig. 2.16 A, 
upper panel), slices treated with Dox for 48 hours showed reduced f-PSPs compared to 
untreated slices (Fig. 2.16 A, bottom panel). This is an indication that Dox inducibly 
caused expression of rtTA and TeTxLC leading to silencing of synaptic transmission. 
To test for motor behavior in the open field, two wild-type mice were injected 
into the striatum with rAAV-hSYN-rtTA and rAAV-Ptetbi-TeTxLC/tdTOM and two 
control mice with rAAV-hSYN-Venus. Motor activity was assessed by amphetamine 
injection before Dox injection (Movies M3 A and B). Locomotor activities of TeTxLC 
infected mice were similar to wild-type mice before Dox injection (Fig. 2.16 C). Four 
days after a single i.p Dox injection, the TeTxLC infected mice showed ipsilateral 
rotation behavior (Fig. 2.16 D, M 3C). The graph in figure 2.16 E shows the rotation 
score before and after Dox injection. After almost 11 weeks of Dox withdrawal the 
rotation scores reduced to nearly the same level as the starting rotation score without Dox 
(Fig. 2.16 E). The observed initial rotation scores (without Dox) could be due to leaky 
expression of the responder virus. However, when Dox was again injected, reactivation 
of TeTxLC took place leading to rapid increase in the rotation scores to levels 
comparable to the rotation scores at the beginning when a single dose of Dox was 
injected (Fig. 2.16 E). Post-hoc anatomical analysis indicate reactivation of tdTOM and 
also no visible structural damage to tissues of the striatum of TeTxLC infected mice 
compared to the Venus injected control (Fig. 2.16 F). 
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Figure 2.16 Inducible rotational behavior in rtTA- and TeTxLC-infected mice  
 (A) A schematic of the electrophysiological recording. A single trial field potential (f-PSP) from control 
and TeTxLC-infected slices (lower panel). (B) Slope of f-PSP in CA3 regions after mossy fiber stimulation 
with increasing stimulation intensities in uninfected (4 slices) and TeTxLC-infected (5 slices) rat 
organotypic hippocampal slices. (C, D) Mice were infected with rAAV-hSYN-rtTA and rAAV-Ptetbi-
TeTxLC/tdTOM. Open field rotational traces with and without Dox treatment and before and after 
amphetamine injection. (E) Rotational scores before and after Dox treatment and scores after Dox 
withdrawal. The large increase in rotational score after 10 weeks of Dox withdrawal is due to reactivtion 
after 2 days of Dox treatment. (F) Post-hoc analysis after Dox reactivation indicates the expression of 
tdTOM in the striatum. The lower panel is the constitutive Venus control. 
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2.3.5 Generation of fast TeTxLC constructs  
 
With an estimated half-life of six days for the TeTxLC, it was expected that reversibility 
of synaptic silencing would take at least several weeks (Fig. 2.15 B and Fig. 2.16 E). It 
was therefore necessary to develop new TeTxLC-variants with shorter half-lives. To 
achieve this, two new TeTxLC variants were designed. In the first case, a degradation 
sequence rich in proline aspartic acid, serine and threonine (PEST) derived from the 
mouse ornithine decarboxylase gene was used (Li et al., 1998, Yamamoto et al., 2003).  
Naturally occurring proteins with PEST domains are usually unstable proteins and 
are rapidly degraded. Deletion of the PEST domain from these proteins dramatically 
increase their half-lives (Ghoda et al., 1989), therefore these regions act as a degradation 
domain. It is now well known that PEST-containing proteins have short half-lives, from 
30 minutes to two hours (Li et al., 1998). It was previously shown that introduction of a 
PEST-containing sequence to the green fluorescent protein reduced its half-life from 24 
hours to 1 hour (Li et al., 1998, Yamamoto et al., 2003). Proteins with PEST sequences 
use the calpain protease system for degradation and also ubiquitin-mediated degradation 
pathways (Fig. 2.17 A) (Bercovich et al., 1989, Rosenberg-Hasson et al., 1989, 
Murakami et al., 1992, Spencer et al., 2004). Taking advantage of this finding (Li et al., 
1998), the PEST sequence was fused to the C-terminus of the TeTxLC to generate a 
TeTxLC-variant called Fast1-TeTxLC (F1-TeTxLC) (Fig. 2.18).  
In a second TeTxLC construct, the N-end rule was applied to further shorten the 
half-life of the TeTxLC and this construct is named Fast2-TeTxLC (F2-TeTxLC) (Fig. 
2.18). The N-end rule states that the N-terminal amino acid of a protein is an important 
factor in determining the half-life of the protein (Varshavsky, 1997a). This is applicable 
to eukaryotic and prokaryotic systems (Varshavsky, 1997a). Previously, it was found that 
on average, a protein’s half-life is correlated with its N-terminal residue. Proteins with 
methionine, serine, alanine, threonine, valine or glycine have half-lives of more than 20 
hours (Varshavsky, 1997a). However, if the N-terminal amino acid is phenylalanine, 
leucine, aspartic acid, lysine or arginine, protein half-lives can be as low as 3 minutes 
(Taxis et al., 2009). Proteins that follow the N-terminal rule are recognized and degraded 
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by the ubiquitin-mediated pathway (Fig. 2.17 B) (Varshavsky, 1997a, b, Taxis et al., 
2009).  
To generate a new TeTxLC with shorter half-life, an N-degron was fused to the 
N-terminus of the TeTxLC. The N-degron is protected at its N-terminus by an amino acid 
sequence recognized by the tobacco etch virus protease  (TEV). The TEV recognition site 
contains seven amino acids (ENLYFQ-X). The protease cleaves between positions 6 and 
7 of the recognition site. Residue X then becomes the new amino terminal upon cleavage 
(in this case, X = phenylalanine) (Taxis et al., 2009). Thus, in this system, cleavage of the 
TEV recognition sequence by TEV would expose the susceptible N-degron for rapid 
protein degradation (Fig. 2.17 B). To make TEV protease mediated cleavage of the N-
degron more efficient, an amino acid sequence from the splicing factor 3b155 
(SF3b155381-424) was introduced in the TeTxLC. The 3b155 domain is recognized by the 
spliceosome subunit p14, which is linked to the TEV (named TEV-p14) (Suzuki and 
Varshavsky, 1999, Spadaccini et al., 2006, Taxis et al., 2009) (Fig. 2.17 B). Thus, TEV-
p14, by binding to 3b155 deprotects N-degron, and therefore targeting the fusion protein 
(F2-TeTxLC) for rapid degradation (Fig. 2.17 B). In summary, a new TeTxLC construct 
was generated called F2-TeTxLC by attaching N-degron and a TEV protease recognition 
site, under the control of a Ptetbi promoter. The other half of the promoter is occupied by 
the TEV protease fused to p14 (the spliceosome subunit). The N-degron can be exposed 
by the expression of the p14-TEV leading to ubiquitination and degradation in the 
proteasome.  
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Figure 2.17 Schematics of the PEST and TEV induced protein instability 
(A) Schematic of calpain and ubiquitin mediated protein degradation involving PEST sequence. (B) TEV 
protease induced protein instability system. The N-degron containing the TEV recognition site with the 
SF3b155381-424 was fused to the N-terminus of the HA-tagged-TeTxLC. Spacers were introduced at specific 
points to allow for proper protein folding. p14 is fused to the N-terminus of the TEV protein. The TEV is 
FLAG tagged at the C-terminus for immunodetection. The construct is under the control of the Ptetbi 
promoter. When TEV is expressed, it binds to the target TeTxLC protein, binding is aided by the 
interaction of p14 with a 40 amino acid fragment (381-424) derived from SF3b155. The interaction directs 
the efficient cleavage of the N-degron by the TEV at the TEV recognition site (ENLYFQ-X). Cutting of the 
N-degron at the TEV recognition site leads to the deprotection of the N-degron, the N-terminus is now the 
newly exposed amino acid (X). The exposed amino acid is ubiquitinated and the fate of the protein is 
determine by the nature of X (X= A, C, G, M, P, S, T and V leads to stable proteins, where as X =D, E, F, 
H, I, K, L, N, Q, R, W and Y render the protein unstable (half-lives =2-30 minutes) (Suzuki and 
Varshavsky, 1999, Taxis et al., 2009). The target protein is poly-ubiquitinated by Ubr1p and degraded by 
the proteasome (Modified from Taxis et al., 2009). 
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Figure 2.18 The different rAAV based TeTxLC constructs 
The first construct is the original TeTxLC with tdTOM for fluorescent imaging, the second construct is also 
the original TeTxLC with C-terminus HA-tag. The third construct is F1-TeTxLC a PEST domain (in black) 
and HA-tag (orange) for immunodetection. The fourth construct is the F2-TeTxLC with TEV in a 
bidirectional cassette expressing both proteins. The last construct is also F2-TeTxLC with tdTOM for 
imaging. All five constructs are under the control of the Ptetbi promoter. 
 
 
 
2.3.6 Functional expression of fast TeTxLC variants in HEK293 cells and in 
         organotypic brain slices  
 
To test whether the newly generated TeTxLC constructs can be expressed in mammalian 
cells, HEK293 cells were transfected with the new constructs and cell lysates were used 
for Western blot analysis with a mouse monoclonal HA antibody (Fig. 2.19 A). Both 
fusion proteins (F1-TeTxLC and F2-TeTxLC) were detected on a Western blot with exp- 
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Figure 2.19 Expression of F1- and F2-TeTxLC constructs 
(A) HEK293 cells were transfected with F1- and F2-TeTxLC with tTA. Cell lysates were run on SDS gel 
and blotted onto nitrocellulose membrane. Immunodetection was done with mouse monoclonal HA 
antibody. The control is an uninfected HEK293 cells. The 88 kDa protein band correspond to the 
approximate molecular weight of F2-TeTxLC and the 75 kDa protein correspond to the estimated 
molecular weight of F1-TeTxLC. (B) Rat hippocampal organotypic slices were infected with the original 
TeTxLC construct (far left), F1- and F2-TeTxLC constructs (middle) and TeTxLC-2A-mKO (far right) 
with hSYN-tTA for two weeks. (C) Cell lysates from the infected organotypic slices were run on SDS page 
and blotted with antibodies against VAMP1, VAMP2 and ß-tubulin. The control slices were uninfected. 
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 ected molecular weights of approximately 75 kDa and 88 kDa, respectively (Fig. 2.19 
A). For a functional assay rat organotypic slices were infected with viruses of F1- and F2-
TeTxLC in addition to tTA (Fig. 2.19 B). The infected tissues were imaged first for 
fluorescence detection of tdTOM and later harvested two weeks after infection and the 
lysates used for Western blot analysis with antibodies against VAMP 1 and VAMP 2. β-
tubulin was used as a control (Fig. 2.19 C). The result of the Western blot clearly 
indicates that F1-TeTxLC and F2-TeTxLC proteins were able to cleave both VAMP 1 
and VAMP 2 (Fig. 2.19 C). 
 
 
2.3.7 tTA- and rtTA-dependent induction of F1- and F2-TeTxLC 
 
In order to demonstrate that the new TeTxLC variants are inducible, dissociated primary 
neurons were infected with either rAAV-Ptetbi-F1-TeTxLC/tdTOM only (Fig. 2.20 A, 
upper left panel) or with rAAV-Ptetbi-F1-TeTxLC/tdTOM + rAAV-hSYN-tTA (Fig.2.20 
A, upper right panel) for two weeks. The same experiment was repeated with the rAAV-
Ptetbi-F2-TeTxLC/tdTOM with or without tTA. The results indicate that gene expression 
occurred only in the presence of tTA as measured by tdTOM expression.  
To show Dox dependent gene activation, dissociated primary neurons were 
infected with rAAV-Ptetbi-F1-TeTxLC/tdTOM + rAAV-hSYN-rtTA for two weeks in the 
absence of Dox (Fig. 2.20 B, upper left panel) and in the presence of 1 µg/ml Dox for 
forty-eight hours (Fig. 2.20 B,  upper right panel). The same experiment was repeated 
with rAAV-Ptetbi-F2-TeTxLC/tdTOM + rAAV-hSYN-rtTA (Fig. 2.20 B lower panel). 
The results indicate that both systems are tTA and rtTA-dependent and therefore 
regulatable. 
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Figure 2.20 tTA- and rtTA-dependent induction of F1 and F2-TeTxLC 
(A) Dissociated primary neurons infected with rAAV-Ptetbi-F1- and F2-TeTxLC only (left panels), and 
with rAAV-hSYN-tTA (right panels) for two weeks indicate gene expression only in the presence of the 
activator. (B) Dissociated neurons infected with rAAV-Ptetbi-F1- and F2-TeTxLC + rAAV-hSYN-rtTA in 
the absence of Dox (left panels) and in the presence of Dox for 48 hours indicate rtTA-dependent gene 
activation only in the presence of Dox. 
 
 
 
2.3.8 Repeated cycles of silencing and un-silencing of synaptic transmission using 
         F1- and F2-TeTxLC, assessed by amphetamine-induced rotational behavior  
 
In the previous amphetamine-induced rotational behavior with the original TeTxLC, it 
was observed that the behavior phenotype can be reversed, however, reversal took more 
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than 8 weeks to complete. This therefore makes the system unsuitable for rapid reversible 
silencing of synaptic transmission. To overcome this, new TeTxLC variants were 
generated as described above (Fig. 2.17 and 2.18). To test the applicability of the new 
TeTxLC variants for rapid reversible silencing of synaptic transmission, wild type mice 
(3) were injected with rAAV-Ptetbi-F1-TeTXLC/tdTOM + rAAV-hSYN-tTA into the 
striatum. Two weeks after virus injection, the mice were subjected to amphetamine-
induced rotational behavior test in the open field as described above. The total number of 
rotations made was recorded as rotation scores (Fig. 2.21 A). After the first recording, the 
mice were put on Dox in the drinking water to shut down the expression of tTA. The 
rotation behavior experiment was repeated over the period of Dox treatment. It was 
observed that the rotation score decreased by about 50 % (from 150 rotation to around 75 
rotations) within two weeks of Dox treatment (Fig. 2.21 A). And within three weeks, the 
rotation score decreased to 45 and remained fairly constant by the 4th week. Reactivation 
took place when the mice were withdrawn from Dox within a week (Fig. 2.21 A). A 
second cycle of reversible silencing was repeated and the results nearly the same as the 
first cycle. It therefore implies that a complete cycle of silencing and un-silencing of 
synaptic transmission is possible with the F1-TeTxLC/tdTOM within 3 weeks. However, 
there is a significant rotational behavior after the three weeks, which may be due to the 
leakiness of the responder. 
A similar experiment was repeated with F2-TeTxLC by injecting rAAV-Ptetbi-F2-
TeTxLC/TEV in combination with either rAAV-hSYN-tTA or rtTA into the striatum. 
With the tTA system (Fig. 2.21 B), it was observed that the rotation score decreased by 
more than half within two weeks, and almost to the basal level by the 3rd week. On 
reactivation by Dox withdrawal at the end of the fourth week, rotation scores returned to 
maximum within a week. However, when Dox was again administered, the decrease in 
rotational score was more dramatic. Within a week after the mice were put back on Dox, 
the rotation score decreased from 150 to about 75 (Fig. 2.21 B, week 6). This was not 
observed with the F1-TeTxLC on reactivation, instead, F1-TeTxLC showed a marginal 
increase in rotation score on Dox administration (150 to 160) (Fig. 2.21 A, week 6). By 
the end of the 2nd week of Dox administration, the rotation score decreased to the basal 
level (Fig. 2.21 B ). 
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With the rtTA system, the mice displayed some amphetamine-induced rotation 
behavior without Dox administration (Fig. 2.21 C). However, two days after a single i.p. 
injection of Dox, the mice displayed robust amphetamine-induced rotation behavior 
reaching as high as 180 rotation scores in 10 minutes from the basal value of 25. This is 
more than 7 fold increase in rotation score. When no Dox was administered for a week, 
the rotation score decreased sharply in two of the mice to almost baseline level (34 
rotations in 10 minutes). The decrease in the observable rotations in the 3rd mice also 
reached the basal level within two weeks (Fig. 2.21 C, day 16). This remained constant 
for one more week. Upon reactivation, the rotation score increased to the maximum level 
and within another one week of Dox withdrawal, the rotation score of one mouse was 
back to the basal level while the other two also showed significant decrease in rotation 
scores. By the end of the second week of Dox withdrawal, the rotation scores of all three 
mice decrease to the baseline. From the rtTA and the tTA data, it is possible to complete 
a cycle of reversible silencing and un-silencing of synaptic transmission within two 
weeks or even less with the F2-TeTxLC. To conclude from this results, the F1-TeTxLC 
and F2-TeTxLC can be used for rapid reversible silencing of synaptic transmission within 
3 weeks and 2 weeks respectively.  
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Figure 2.21 Repeated cycles of amphetamine-induced rotational behavior in F1- and F2-TeTxLC 
injected mice. (A) Three wild-type mice injected into the striatum with rAAV-Ptetbi-F1-TeTxLC/tdTOM + 
rAAV-hSYN-tTA and subjected to repeated cycles of amphetamine induced rotational behavior. Rotation 
was reversed after 3 weeks of Dox treatment in the drinking water. (B) Cycles of amphetamine-induced 
rotational behavior in 2 wild-type mice injected with rAAV-Ptetbi-F2-TeTxLC/TEV + rAAV-hSYN-tTA. 
Rotation behavior is reversed after two and a half week of Dox treatment. (C) Amphetamine induced 
rotational behavior analysis in 3 wild-type mice injected with rAAV-Ptetbi-F2-TeTxLC/TEV + rAAV-
hSYN-rtTA. These mice showed rotational behavior before Dox administration. However, rotational scores 
increased to as high as 200, and reversed to almost basal level after one and a half weeks of Dox 
withdrawal. 
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2.3.9 Application of a genetic mosaic technique to inducibly express TeTxLC in 
         selected neurons  
 
In order to make the inducible expression of TeTxLC a more versatile tool, a new Cre-
dependent genetic switch called the Flip-Excision (FLEX) cassette was generated 
(Schnutgen et al., 2003, Atasoy et al., 2008). In this system, Tag-RFP (red fluorescence 
protein) was fused to rtTA via a 2A peptide linker. This DNA fragment was cloned in 
between 2 loxP sites oriented in opposite direction (lox 2722) (Fig. 2.23) in a reverse 
sense with a cytomegalovirus early enhancer/chicken β actin (CAG) promoter. The 
fusion gene sequences (rtTA-2A-Tag-RFP) will only be expressed when the Cre-
recombinase protein is expressed (Fig. 2.23, middle). In the absence of Cre, there will be 
no gene inversion and therefore no expression of rtTA and Tag-RFP, and the system will 
remain shut. However, in the presence of Cre-recombinase, there will be an inversion at 
the loxP sites and the genes will be oriented under the CAG promoter, leading to 
expression of rtTA and Tag-RFP (Fig. 2.23 B).  
The advantage of this system is that it can be applied in a combinatorial approach 
using the inducible bidirectional F2-TeTxLC and the Cre transgenic mice to specifically 
silenced selected type of neurons only in the presence of Dox (Fig. 2.23, lower section). 
This combinatorial approach will allow for the conditional expression of rtTA in only Cre 
positive cells and therefore only these cells will be silenced on Dox administration. 
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Figure 2.23 Mechanism of action of the FLEX cassette 
(A) rtTA and Tag-RFP were cloned (in a reverse sense) between two loxP sites oriented in opposite 
directions under the control of the CAG promoter and the Woodchuck Posttranscriptional Regulatory 
Element (WPRE) with SV40 polyA. Cre recombinase will cause gene inversion at the loxP sites leading to 
the expression of rtTA and the Tag-RFP protein. A combinatorial expression of Cre, FLEX cassette and 
TeTxLC will lead to silencing of only Cre positive neurons in the presence of Dox. (B) Rat organotypic 
slices infected with only rAAV-FLEX-rtTA-2A-Tag-RFP (left panel) and in the right panel is a 
combination of rAAV-FLEX-rtTA-2A-Tag-RFP and Cre. The red fluorophore is the expressed Tag-RFP 
after Cre- mediated excision. 
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3. DISCUSSION 
 
3.1 Manipulating gene expression and neuronal circuits in the mouse brain 
 
Brain circuits are composed of different neuronal types with diverse functions (Druga, 
2009). Neurons are connected with each other via synapses, and they form complex 
synaptic circuits (Chklovskii et al., 2004). In different brain regions, functional neuronal 
circuits are dedicated for specific functions, such as assembling and integrating sensory 
signals into meaningful relationships, decision-making and motor output responses 
(O'Connor et al., 2009). There is compelling evidence that distributed neuronal circuit 
encompassing different brain regions are involved in learning and also forming memory 
representations, which are encoded in spatiotemporal neuronal activity patterns. There are 
a large number of proteins, which are critically needed in strengthening and weakening 
functional synaptic connections (Luscher et al., 2000).To understand their function, it is 
important to develop genetic tools to inducibly inactivate genes of interest in specific 
brain regions (Mayford et al., 1996). Moreover, silencing synaptic transmission between 
synaptically connected neurons can help to reveal their role in learning and memory 
(Yamamoto et al., 2003, Nakashiba et al., 2008). 
In my PhD study, I focused on two major goals: (1) to develop a novel genetic 
approach for inducible, cell-type-specific gene deletion in the brain and (2) reversible 
silencing of synaptic transmission. Recombinant adeno-associated viruses were 
developed, which were equipped with the tetracycline (Tet)-controlled genetic switches 
to investigate the role of specific genes and cell types in learning and memory 
consolidation processes.  
 
 
3.2 The rAAV gene delivery system  
 
Our study has demonstrated the usefulness of the recombinant adeno-associated virus 
(rAAV) for gene expression in vitro and in vivo. Unlike the transgenic approach, the 
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rAAV system has several advantages such as easy production and handling (Grimm et 
al., 1998). It permits excellent infection of neurons in vitro and in vivo within two weeks 
and guarantees expression in vivo for many years (Klein et al., 2002). By stereotaxic 
injection, the virus can be targeted to any brain region. The extent of infection can be 
controlled by decreasing the number of virus particles injected in the brain. The use of D-
mannitol by intraperitoneal injection creates a hyperosmotic condition in the brain, 
facilitating virus diffusion, thus increasing the infection diameter (Fig. 2.10). 
One major limitation of the rAAV system is the cloning capacity of the virus. For 
maximum gene expression, it has been shown that 4.7 kb of DNA between the two ITRs 
is sufficient for effective packaging. Therefore genes larger than 4.7 kb are poorly 
packaged, with generally poor expressions. However, in this study, we cloned a gene of 
about 5.2 kb between the two ITRs and still obtained good expression. The other 
disadvantage of the rAAV is the loss of ITR sites when expressed in E. coli. The 
repetitive nature of the ITR sequences makes them unstable when propagated in E.coli. 
Since the ITRs are vital for virus packaging, it is important to ensure that they remain 
intact. To overcome this, E coli strains defective in recombination such as SURE 
competent Cells (Stratagene, La Jolla, California, USA) have been found to maintain 
stable ITRs. However, it is important to check the presence of the ITR sites for every 
transformation by restriction digest with Sma I. 
 
 
3.3 rAAV-mediated gene expression in the mouse nervous system 
 
rAAV2 has been used predominantly to demonstrate infectivity in the CNS in regions 
such as hippocampus, striatum, globus pallidus, substantia nigra and spinal cord (Wang et 
al., 1998, Alisky et al., 2000). In this study, however, a cross-packaging of AAV1 and 
AAV2 was used. In rat dissociated neuron cultures and organotypic slices, we observed 
strong expression by rAAV1/2. In many instances, using a neuron specific promoter such 
as the human synapsin promoter, besides neurons, we unexpectedly also observed 
expression in glia cells in vitro. However, in different brain regions in vivo, we observed 
expression, which was neuron-specific. Interestingly, expression was largely restricted to 
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neurons in cortical layer 2/3 and layer 5, but no expression in layer 4 and 6 (Fig. 2.6, 2.9 
and 2.11). This interesting feature of rAAV1/2 can be advantageous to selectively target 
layer 2/3 and layer 5 cortical neurons. In deeper brain regions, strong expression was 
observed in the granule cells of the dentate gyrus including the mossy fibers and CA1 and 
CA3 pyramidal neurons. In the striatum, medium spiny neurons and interneurons also 
showed good expression. This demonstrates that AAV1/2 can be used effectively for 
targeting gene expression in different brain regions. 
 
 
3.4 Inducible gene expression: kinetics of gene regulation in neurons 
 
The Tet-inducible gene expression systems have been used extensively in eukaryotic 
systems. In this investigation, we have demonstrated the use of the Tet-inducible systems 
for in vitro and in vivo long-term gene expression in the mouse brain. In combination 
with reporters such as the firefly luciferase under control of the Tet promoter, we 
elucidated the time course of tTA/rtTA-dependent gene activation/inactivation in the 
mammalian brain. The kinetics of the tTA system in this study looked nearly the same as 
that of the rtTA (Fig. 2.1-2.4). With both tTA and rtTA systems, an approximately 200 
fold increase in gene regulation was observed. However, the Tet promoter showed basal 
expression in the absence of the activators (tTA/rtTA), which could be due to the ITR 
enhancer activity onto the Tet promoter (Fig. 2.1- 2.4) (Hatfield and Hearing, 1991). 
When the systems were used with luciferase for repeated cycle of gene regulation, 
it was observed that at the end of each ‘OFF’ state, there was a residual luciferase 
activity. This observation could be due to the fact that gene expression was not 
completely switched-off. This activity was carried onto the next cycle, giving an 
impression of higher basal levels of luciferase activity at the subsequent ‘OFF state (Fig. 
2.2 B). With the in vivo Dox-dependent gene regulation, Dox efflux was found to play a 
crucial role in the length of period of each activation/inactivation cycle. Dox gets trapped 
in fatty tissues in the brain and its clearance takes longer in the brain than in tissue culture 
medium. Therefore, with the tTA and the rtTA systems, it takes longer time to reactivate 
(6 days) and inactivate (6 days) Dox-dependent gene expression, respectively. Decreasing 
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Dox concentration should help to shorten the gene regulation cycle times. In summary, in 
vivo gene expression cycles with the Tet systems can be applied to control many other 
genes. It is important to bear in mind that the off-rate of gene expression is in part also 
strongly dependent on the half-life of the regulated protein. Proteins with shorter half-
lives such as firefly luciferase (3 hours) or specially engineered proteins with shorter 
half-lives can be used for rapid cycles of gene regulation.  
Comparative analysis of firefly luciferase (Photinus pyralis fLUC) and the 
Brazilian luciferase (Cratomorphus distinctus bLUC) in this study showed that bLUC 
emits more photons (by about 60 times) than the fLUC (Fig. 2.5). It was expected that the 
regulatory factor of the bLUC should be similar to that of the fLUC. However, a 1000 
fold increase in regulation of the bLUC was observed compared to 300 fold of the fLUC 
(Fig. 2.5 B). One possibility is that the transcriptional units in the two Tet responder 
vectors were modestly affected by the cloned genes.  
It is clear from these studies that both the tTA and the rtTA systems can be 
effectively used for inducible and reversible control of gene expression. However, the 
rtTA system has a key advantage in that it can be switched-on rapidly, within hours, thus 
providing a great possibility to investigate neurophysiology and behavior before and after 
gene deletion. With the tTA system, however, gene expression must be kept off by Dox, 
and upon Dox removal, it takes several days for gene re-activation. Importantly, if gene 
expression is kept off by Dox during prenatal development, re-activation of gene 
expression upon Dox removal can take several months (Bejar et al., 2002, Zhu et al., 
2007).  
 
 
3.5 Inducible, cell type-specific gene knockout 
 
In this current study, the versatility of Dox-induced, rtTA-dependent Cre-mediated gene 
recombination and deletion was demonstrated. It was shown that a combination of 
rAAVs expressing the Cre-recombinase and rtTA could be used for conditional, site-
specific gene recombination in targeted brain regions in the mouse nervous system. 
Expression of Cre and rtTA in the presence of Dox showed robust gene recombination in 
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the transgenic Rosa26R mice only in regions infected with the viruses (Fig. 2.7 and 2.8). 
However, the observed very low basal recombination in control mice without Dox could 
be due to leakiness of the responder viruses (iCre/tdTOM). With multiple viruses 
infecting each neuron, low basal activity by Ptetbi also accumulates and this could lead to 
recombination in the absence of Dox. This leakiness could also be due to the proximity of 
the viral ITRs to the responder genes. It has been reported that ITRs in some instances act 
as enhancers to nearby genes (Hatfield and Hearing, 1991). This basal leakiness could be 
reduced by a number of ways; the first possibility is by titrating the responder virus to the 
activator, in this case, the number of responder particles are reduced significantly thus, 
decreasing the cumulative effect of multiple virus infection. This was clearly 
demonstrated in this study when the responder virus was diluted (Fig. 2.8). The second 
possibility is to use genetic insulators, which acting as a barrier to the ITR, can reduce the 
enhancer activity of the ITR (Burgess-Beusse et al., 2002).  
Using the rAAV systems with Cre and rtTA we have demonstrated knockout of 
the NMDA receptor 1 gene in the barrel cortex of NR1-2lox mice within a week of 
putting the virus-injected mice on Dox. With this approach, we electrophysiologically 
demonstrated loss of NMDA charge transfer as a result of functional loss of the NMDA 
receptor gene. This method provides a powerful approach to selectively target a specific 
brain region for cell type-specific inducible gene knockout.  
 The role of motor cortex NMDA receptors in associative learning and memory 
was investigated in this study using the Tet-inducible system and NR1-2lox transgenic 
mice. rAAV expressing the activator (rtTA) and the responder (iCre/tdTOM) were 
injected into the mouse motor cortex. We demonstrated that Dox treatment for 1 week 
was sufficient for complete knockout of the NMDA receptor in the barrel cortex, leading 
to a significant reduction in NMDA current. This combinatorial approach was also 
applied to the motor cortex of NR1-2lox transgenic mice. One issue was that the motor 
cortex is very large (about 3 mm in length and 0.5-1.5 mm wide) and therefore a D-
mannitol procedure was applied to increase the expression diameter (Fig. 2.10). We 
successfully targeted 70 % of the motor cortical region, with 90 % of the neurons within 
this region. After Dox treatment, we expect efficient deletion of the NMDA receptor 1 
gene. Would this extent of knockout give us a behavioral phenotype? It was shown 
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previously that a little over 30 % of deletion of the NMDA receptor and between 10-20 % 
deletion of AMPA receptor in the lateral amygdala was sufficient to cause memory 
deficit in fear related learning (Rumpel et al., 2005). We therefore conjectured that more 
than 70 % of NMDA receptors knocked out in the motor cortex should be sufficient to 
produce behavioral phenotypes in the Skinner box test and classical conditioning of 
vibrissae responses (Thompson and Disterhoft, 1997). 
 
 
3.6 Constitutive expression of TeTxLC-2A-mKO 
 
In the current investigation, we showed that the TeTxLC and a red fluorescent protein 
variants, mKO, could be expressed constitutively with the 2A peptide (Tang et al., 2009) 
leading to the generation of two functional proteins (Fig. 2.14). With this approach, we 
confirmed that the 2A peptide fused to the C-terminus did not affect the TeTxLC 
functional activity and both proteins were expressed at nearly equal levels (Tang et al., 
2009). The 2A approach offers a versatile tool for multiple gene expression from a single 
promoter. The TeTxLC-2A expression was easily detectable by both Western blot and 
immunofluorescence using the 2A-specific antibody (Fig 2.12 and 2.14). TeTxLC 
expressing neurons can be easily identified because they also express mKO. The 
disadvantage of this approach is that the system cannot be regulated.	  	  
 
3.7 Reversible silencing of synaptic transmission with TeTxLC 
 
Genetic tools provide a potent approach to establishing the relationship between the 
activity of specific neuronal circuits and behavior. Several genetic strategies for 
reversible silencing of synaptic transmission have been described (Karpova et al., 2005, 
Lerchner et al., 2007). In this study, we have expressed the tetanus toxin light chain 
(TeTxLC) either constitutively (human synapsin promoter) or inducibly (Ptetbi promoter), 
for permanent and reversible silencing of synaptic transmission, respectively. TeTxLC is 
known to selectively cleave the synaptic vesicle protein VAMP2, thus leading to 
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abrogation of Ca2+-induced fusion of synaptic vesicles, the result of which is the 
termination of neurotransmitter release at the presynaptic terminals. In this study, we 
have confirmed by Western blot that TeTxLC specifically cleaves VAMP2 (Schiavo et 
al., 1992a, Sweeney et al., 1995). However, to our surprise, VAMP1 also disappeared 
(Fig. 2.12).  Electrophysiologically, we demonstrated that the TeTxLC silenced neurons 
were capable of generating action potentials, which were blocked by tetrodotoxin. We 
also demonstrated that the postsynaptic cells responded to exogenous glutamate 
application. This confirmed that the TeTxLC preferentially blocks presynaptic 
transmission without affecting the neuronal viability. 
 Behaviorally, we also showed that injection of a TeTxLC expressing virus into 
the striatum of living mice produced a behavioral phenotype in amphetamine-induced 
rotational studies as well as in tail suspension tests (Fig. 2.14 and 2.15). The silencing in 
the striatum by TeTxLC mainly involves dopaminergic neurons. The dopaminergic 
neurons of the striatum relay dopaminergic signals from the substantia nigra to the motor 
and sensory neurons of the cortex. These neurons were unilaterally silenced with the 
inducible TeTxLC. The amphetamine-induced rotation behavior observed with the Tet-
inducible systems was reversed after more than 10 weeks of Dox treatment or 
withdrawal, with the tTA and rtTA systems, respectively. Post-hoc analysis by 
fluorescent imaging indicated that the medium spiny neurons of the striatum remained 
morphologically unchanged. There were also no observable ‘holes’ in the brain regions 
infected with the virus, indicating that there were no lesions in the striatum. This is an 
indication that the neurons are likely alive. Rotation scores (number of rotations made in 
10 minutes) of as high as 350 were observed with the tTA system, while up to 160 were 
observed with the rtTA system (Fig. 2.15 and 2.16). The apparent difference in the 
rotation score between the tTA and the rtTA mice could be due to the quality of the tTA 
and the rtTA viruses since the responder virus was the same. The basal rotation observed 
with the rtTA system is most likely due to the leakiness of the responder.  
The long period taken to observe a decrease in rotation behavior of the TeTxLC 
injected mice to the basal level upon Dox administration (tTA) and Dox withdrawal 
(rtTA) was most likely due to the long half-life of the TeTxLC of approximately six days 
(Habig et al., 1986).  We thus sought to generate TeTxLC variants with reduced half-life. 
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3.8 TeTxLC variants with short half-life 
 
To decrease the half-life of the TeTxLC protein, two different approaches were 
employed. The first approach involved the use of the PEST sequence fused to the C-
terminus of the TeTxLC. With this, the half-life of the TeTxLC decreased significantly, 
as judged from the amphetamine-induced rotation behavior. In this study using the F1-
TeTxLC (PEST), the rotation scores decreased to less than half of the initial value (150 to 
about 70 rotations in 10 minutes) within two weeks compared to the over 6 weeks taken 
by the original TeTxLC to decrease to half of the original rotation score (Fig. 2.21). With 
the F1-TeTxLC, the rotation returned to basal levels within 3 weeks of Dox 
administration.  
This finding is a confirmation of the outcome reported by Yamamoto et al., 2003. 
Using the PEST sequence in transgenic mice, the authors demonstrated the reversal of 
rotation behavior in the mice after 3 weeks of Dox treatment. In a previous study, 100 % 
reversal of rotation could not be achieved (Lerchner et al., 2007). The reason for this 
residual rotational behavior could be due to leakiness of the responder, to the prolonged 
silencing of neurons by the TeTxLC, or the effects of repeated injections of 
amphetamine, leading to a directional bias in the rotational behavior test. This could be 
investigated further by virus titration of the responder. The rapid reversibility of the 
system was confirmed when Dox was withdrawn within one week, with the rotation score 
returning to the initial value of about 150 rotations in 10 minutes.  
To improve the system further and make it faster for rapid reversible silencing, a 
second approach was used, called the TEV protease induced protein instability (TIPI) 
method (Fig. 2.17) (Taxis et al., 2009). TIPI is used to decrease the abundance of proteins 
expressed in cells. In this method, N-degron (Spadaccini et al., 2006, Taxis et al., 2009) 
with a TEV recognition site was fused to the N-terminus of TeTxLC while the C-
terminus was fused to a PEST sequence. The resulting TeTxLC variant was named F2-
TeTxLC. Amphetamine-induced rotational behavior with this new TeTxLC variant 
showed a rapid decrease in rotation score. Upon injection of a single dose of Dox, the 
rotation score increased to a peak of 160 rotations in 10 minutes within 2 days (Fig. 2.21 
C). This value decreased to baseline within a week of Dox withdrawal, though a residual 
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baseline rotation was still observed. The decline in rotation score may even be faster if 
the experiments were done on a daily basis for two weeks. However, one has to take into 
account that repeated injection of amphetamine on such short time scale could present 
other problems such as anxiety, pain and edema, thus leading to sluggishness in motor 
activity. 
 Another factor, which could affect the rapidity of the system, could be Dox 
efflux. As shown earlier in this study with firefly luciferase, it took approximately 6 days 
for Dox to be cleared from the brain tissues (Fig. 2.3). Judging from this, the half-life of 
the F2-TeTxLC could be shorter but other factors also play a role in determining the half-
life. A different way to determine quantitatively the half-life of the F1-TeTxLC and F2-
TeTxLC is via Western blot. The main pitfall in this approach is the leakiness of the 
responder with plasmid DNA transfection into HEK cells, which in small quantities can 
greatly influence the result of the degradation experiment. A serial titration of the 
responder plasmid DNA against the activator could overcome this problem.   
 In this study, it was found that tagging of the TeTxLC at both terminals had no 
effect on the functionality of the protein (Fig. 2.19 and 2.21). Cleavage of VAMP1 and 
VAMP2 was observed in all instances of the tagged TeTxLC expression in vitro (with 
organotypic slices) and in vivo in the striatum. TIPI could be a great tool to strongly 
decrease the half-lives of proteins and, in combination, with the Tet-inducible gene 
expression system could be used for conditional control of protein levels (Taxis et al., 
2009). 
 
 
3.9 Flip-Excision (FLEX) vector / Cre transgenic mice allow for cell type-specific 
      inducible control of TeTxLC expression 
 
Genetic mosaic techniques provide powerful tools for investigating gene functions in the 
nervous system of mammals and other eukaryotic organisms. For example, the genetic 
mosaic techniques make it possible to investigate homozygosity of mutations at defined 
points in an organisms’ development (Zugates and Lee, 2004). One such tool is the Flip 
Excision switch inversion technique (FLEX) (Schnutgen et al., 2003, Atasoy et al., 2008). 
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This system takes advantage of the ability of the Cre recombinase to excise or invert a 
DNA fragment flanked by loxP sites and also the availability of wild-type and spacer 
variant loxP sites. In this study, we have developed a FLEX vector, which expresses two 
genes (rtTA/TagRFP) linked by a 2A peptide in an antisense orientation. The FLEX 
vector expresses the desired gene products only in Cre positive cells. This tool can be 
used in a combinatorial approach with the Tet-inducible systems to express TeTxLC in 
only Cre positive neurons. In this case, with Dox administration, only the Cre-positive 
neurons will be silenced.  
 
 
3.10 Future perspective 
 
This study was largely focused on engineering novel genetic tools for reversible 
manipulation of gene expression and silencing of synaptic transmission. In combination 
with the transgenic mice, the rAAV systems can be used to delete any gene of choice. 
The inducible expression of TeTxLC is a promising tool to study how silencing of 
defined neural circuits in the mammalian brain affect animal behavior. These tools can be 
applied to investigate a wide variety of neurobiological questions, including learning and 
memory consolidation processes. With the FLEX vector and Cre transgenic mice 
combined, it should be possible to target the TeTxLC expression in specified neuron 
types, such as dopaminergic and different inhibitory neurons. The rAAV systems 
described here can be used successfully for precise targeting of different brain regions, 
with a possibility to even deliver gene-products with therapeutic potentials to treat some 
neurological conditions such as the Parkinson’s disease.  
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4. MATERIALS AND METHODS 
 
4.1 Materials  
 
4.1.1 List of mouse lines 
 
C57BL/6 wild-type, NMRI albino mice, Rosa26R (Soriano, 1999) and NR1-2lox 
(Niewoehner et al., 2007) transgenic mice were housed under standard conditions in a 12 
hr light/dark cycle in Makrolon cages type 2A with food and water. All procedures were 
performed in accordance with governmental regulation, German law for animal 
protection. 
 
 
4.1.2 Reagents 
 
Agarose        Invitrogen 
APS          Sigma 
Aquamount        Polysciences 
5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside (X-gal)  Gerbu 
Bromophenol blue       IBI 
BenchMark™ Pre-Stained Protein Ladder    Invitrogen 
Bovine serum albumin (BSA)     Sigma 
Dual-Luciferase® reporter 1000 assay system    Promega 
3,3'-Diaminobenzidine (DAB)     Fluka 
DMSO         Sigma 
EDTA         Merck 
Ethanol        Roth 
Ethidium bromide       Serva 
Glycerol        Merck 
Hydrogen peroxide (H2O2) (30 %)     Fluka 
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Heparin column        Amersham 
Isofluran         Baxter 
Isopropanol         Fluka 
Ketamine        Inversa 
Licain (Lidocain)       Delta select 
β-Mercaptoethanol       Sigma 
Normal goat serum        Vector 
Penicillin/Streptomycin      Gibco 
Polyacrylamide       Bio Rad 
Paraformaldehyde (PFA), 37 %     Merck 
Potassiumferrocyanid (K6Fe (CN)6)     Sigma 
Potassiumferricyanid (K3Fe (CN)6)     Sigma 
Phenol/Chloroform       Roth/Merck 
Sodium dodecyl sulfate (SDS)     Serva 
Sodium acetate       Merck 
Salmon sperm DNA       Roche 
Triton X-100        Merck 
TEMED        Bio Rad 
Trizma         Sigma 
Xylazine        Bayer 
ECL kit,         Amersham  
 
 
4.1.3 Antibiotics  
 
Ampicillin        Sigma 
Doxycycline        Sigma 
Kanamycin        Sigma 
Penicillin/Streptomycin      Gibco 
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4.1.4 Enzymes 
 
Unless otherwise stated, all restriction endonucleases from New England Biolabs 
Benzonase        Sigma 
E.coli DNA-polymerase1 (Klenow fragment)   Roche 
T4-DNA ligase       Roche 
Taq-DNA-Polymerase      Gibco BRL 
Phusion® High-Fidelity DNA Polymerase    NEB 
 
 
4.1.5 Antibodies 
 
Anti-2A peptide (Rabbit polyclonal)     Millipore 
Anti-β-tubulin (Mouse monoclonal)      Millipore 
Anti-Cellubrevin (Rabbit polyclonal)     abcam 
Anti-Cre (Rabbit polyclonal/ mouse monoclonal)   Convance 
Anti-Flag (Rabbit polyclonal)     abcam 
Anti-GFP (Mouse)       Clontech 
Anti-HA (Mouse monoclonal)     abcam 
Anti-NeuN (Mouse)       Chemicon 
Anti-rabbit FITC secondary antibody     Jackson Immuno 
Research 
Anti-Synaptophysin (Goat polyclonal)    Santa Cruz 
Anti-Synaptotagmin II (Goat polyclonal)    Santa Cruz 
Anti-VAMP1 (Rabbit polyclonal)     abcam 
Anti-VAMP2 (Rabbit polyclonal)     abcam 
 
 
4.1.6 Primers/Nucleotides 
 
Deoxyribonucleotide (dNTP)      MBI 
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(1) Primers for cloning pAAV-hSYN-TeTxLC-2AKO 
GD_TTx-2A-KO EcoR1 S  ATAATGAATTCAGGTATGCCGATCACCATCA 
GD_TTx-2A-KO Xho1 AS  TTAAATCTCGAGTAAGCGGTACGGTTGTA 
 
(2) Primers for cloning pCAG-itTA 
GD_CAGitTABamH_S  AGAAGGGATCCCTTACCATGTCTAGACTGG 
GD_CAGitTAXhoAS  AGATCCTCGAGCATCACAGCATATCCAGGT 
 
(3) Primers for cloning pFLEX_CAG_rtTA-2A-TagRFP 
GD_RFPBamHI_S   GCTCGGATCCATGGTGTCTAAGGGCGA 
GD_RFPHindIII_AS   TGCAAAGCTTGAATTCTTACTTGTACAGC 
(4) Primers for cloning pAAV-Ptetbi-bluc/Venus 
GD_ElucHind3_S   CGATAAGCTTACGCGTGCTAGCGCATGCAGA 
GD_ElucSpeI_AS   TGTCTGACTAGTGGCGGCCGCTCTAGATTA 
 
 
4.1.7 Escherichia coli Strains 
 
DH10B        Invitrogen 
SURE cells        Stratagene 
Top 10         Invitrogen 
 
 
4.1.8 Equipments 
 
Amicon Ultracel        Millipore 
Biofuge fresco Centrifuge      Hereaus 
Biophotometer       Eppendorf 
Biotic® Lumi-10 luminometer     Macherey-Nagel 
Concentrator 5301 (SpeedVac)     Eppendorf 
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Cover slips (24x50 mm)      Roth 
DC Temperature control Unit      FHC 
Falcon tubes         Nalgene 
Heating Pad        FHC 
Kopf Stereotaxic Instrument       Kopf Instruments 
Labofuge 400L Centrifuge      Hereaus 
LSM-Pascal Confocal Microscope     Zeiss 
Leica MZ6 stereo Microscope     Leica 
MicroAmp tubes (200 µl)       Perkin Elmer 
Micropipette Puller p-97      Sutter Instrument 
Maxi and mini prep kits      Qiagen 
Optimal LE 80K ultra centrifuge     Bechman 
PCT Thermocycler GeneAmp PCR-System 9600   Perkin Elmer 
Safe-lock eppendorf tubes (1.5 and 2 ml)    Eppendorf 
TSE VideoMot       TSE systems 
Spritzenpump LA-100      Landgraf  
         Laborsysteme 
Thermistor Probe       FHC 
UV-Spectrophotometer Ultrospec 3000    Pharmacia 
Uvette         Eppendorf 
Vibratom VT1000S       Leica 
Whatman paper 3 MM      Whatman 
Zeiss Axiovert 200 M       Zeiss 
 
 
4.1.9 Special software 
 
Adobe Illustrator CS4       Adobe Systems 
Adobe Photoshop CS4      Adobe Systems 
DNA Strider 1.4       CEA 
Gene Construction kit 3.0      Textco 
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Microsoft Word for Mac      Microsoft Corp. 
Microsoft Excel for Mac      Microsoft Corp. 
Microsoft PowerPoint for Mac     Microsoft Corp. 
Editseq        DNASTAR 
ImageJ         NIH, USA 
VideoMot         TSE System 
iMovie         Apple 
 
 
4.1.10 Solutions 
 
1 x PBS:       123 mM NaCl 
        2.7 mM KCl 
        1.4 mM KH2PO4 
        4.3 mM Na2HPO4, pH  
        pH 7.4, 1 liter H2O 
 
1 x PBS-T:       1x PBS, 
        0.05 % Tween20  
 
1 x PBS-MK:       1xPBS, 1mM MgCl2 
        2.5 mM KCl 
 
10 x DNA loading buffer:     30 % Glycerol 
        0.25 % Bromophenol blue 
        0.25 % Xylencyanol 
        25 mM EDTA 
 
1x TAE Buffer:      40 mM Tris 
        5 mM Sodium acetate 
        2 mM EDTA, pH 8.3 
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        1 liter H2O 
 
Day 1 Buffer:       1 % BSA 
        0.3-0.5 % Triton X-100 
        1 x PBS 
 
Day 2 buffer:       Day 1 buffer diluted 1:3  
in 1x PBS 
 
DAB staining solution:     0.04 % DAB 
        20 mM Tris, pH 7.6 
        7.5 x 10-3 % H2O2 
 
SDS-Gel: 
a) Separation gel (10 %):     4.1 ml H2O 
        3.3 ml polyacrylamide 
        2.5 ml Tris-HCl (1.5M)  
        pH 8.8, 100 µl of 10 % SDS 
        10 µl TEMED 
        32 µl of 10 % APS 
 
b) Stacking gel (4 %):      6.1 ml H2O 
        1.3 ml Polyacrylamide 
        2.5 ml Tris HCl (0.5 M) 
        pH 6.8, 100 µl of 10 % SDS 
        10 µl TEMED, 100 µl APS  
 
WB-Running buffer (10x):     250 mM Trizma base 
        1.92 M Glycine 
        1 % SDS 
        1 liter dH2O, pH 8.3 
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WB-Blotting buffer (1x):     25 mM Trizma base 
        192 mM Glycine 
        10 % (v/v) Methanol 
 
WB-Sample (Lämli) buffer (5x):    500 mM DTT 
        10 % (w/v) SDS 
        50 % (v/v) Glycerol 
        250 mM Tris/HCl pH 6.8 
        0.5 % bromophenol blue 
        10 % 2-Mercaptoethanol  
        just before use  
 
Coomassie staining solution:     2.5 % (w/v) Coomassie- 
Brilliant-Blue 
        4 % (v/v) Methanol 
        45 % dH2O 
        10 % (v/v) Acetic acid 
 
Coomassie destaining solution:    7.5 % glacial acetic acid 
        5 % Methanol, 1 liter H2O 
 
4 % Paraformaldehyde:     200 g paraformaldehyde 
        2.5 liter dH2O,  
        10 M NaOH 
        until solution becomes clear 
        add 2x PBS 1:1, pH 7.3 
 
LB medium:        1 % (w/v) Bacto-Trypton, 
        0.5 % (w/v) Yeast extract 
        1 % NaCl, 1liter H2O 
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2YT medium:       2.6 % (w/v) Bacto-Trypton 
        1.6 % (w/v) Yeast extract 
        0.8 % NaCl, 
        3 liter dH2O, pH 7.5 
 
 
4.2 Methods 
 
 
4.2.1 Standard molecular biology methods 
 
All standard molecular biology procedures used in this study including cloning, 
transformation of competent E.coli cells and culturing of bacteria, transfection of 
HEK293 cells, gel electrophoresis and PCR techniques were derived from already 
published protocols (Ausubel et al., 1989, Sambrook and Russell, 2001) 
 
 
4.2.2 rAAV plasmids 
 
Table 1 List of plasmids used in this study 
 
pAAV-hSYN-itTA (Zhu et al., 2007) 
pAAV-CMV-tTA Rolf Sprengel 
pAAV-Ptetbi-iCre-tdTOM (Zhu et al., 2007, Cambridge et al., 2009) 
pAAV-Ptetbi-fLUC-tdTOM Dogbevia, G 
pAAV-hSYN-rtTA Hasan, M.T 
pAAV-hSYN-tTA-2A-mKO (Tang et al., 2009) 
pAAV-hSYN-TeTxLC-2A-mKO Dogbevia, G 
pAAV-Ptetbi-TeTxLC-tdTOM Spieler, K 
pAAV-Ptetbi-F1TeTxLC-tdTOM Dogbevia, G 
pAAV-Ptetbi-F2TeTxLC-tdTOM Dogbevia, G and Kneisel, N 
pAAV-Ptetbi-HATeTxLC-tdTOM Dogbevia, G and Kneisel, N 
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pAAV-Ptetbi-F2TeTxLC-TEV Dogbevia, G and Kneisel, N 
pAAV-hSYN-rLUC Dogbevia, G 
pAAV-CAG-itTA Dogbevia, G 
pAAV-hSYN-bLUC Dogbevia, G and Kneisel, N 
pAAV-Ptetbi-bLUC-Venus Dogbevia, G and Kneisel, N 
pAAV-hSYN-tTA-2A-TEV Dogbevia, G and Kneisel, N 
pAAV-CAG-FLEX-rtTA-2A-TagRFP Dogbevia, G and Kneisel, N 
pAAV-CAG-TetR-Pro-2A-RFP Dogbevia, G 
pAAV-hSYN-TetR-Pro-2A-mKO Dogbevia, G 
pAAV-hSYN-TetR-Pro Dogbevia, G  
pAAV-hSYN-TetR-SP1 Dogbevia, G 
pAAV-hSYN-TetR-Oct1 Dogbevia, G  
 
 
4.2.3 Construction of F1-TeTxLC plasmid 
 
The F1TeTxLC was designed as an improved variant of the original TeTxLC construct 
(pAAV-Ptetbi-TeTxLC/tdTOM). The construct was designed by introducing 122 bp 
sequence of the hemagglutinin tag (3x HA) to the N-terminus and 121 bp PEST sequence 
to the C-terminus. For easy cloning into the original vector backbone, a Pme1 restriction 
site was introduced at the N-terminus and a HindIII at the C-terminus. The entire 
sequence (1740 bp) was synthesized by GENEART into a kanamycin resistant vector 
(pMK-RQ) using SFiI cloning sites and named 1049267_TeTxLC-SF_pMK-RQ. The 
synthesized TeTxLC (1740 bp) was cut out with PmeI and HindIII and cloned into the 
vector pAAV-Ptetbi-TeTxLC/tdTOM in which the original TeTxLC was cut out with 
EcoRV/HindIII. The new plasmid generated was called pAAV-Ptetbi-F1TeTxLC/tdTOM.  
 
 
4.2.4 Construction of F2-TeTxLC plasmid 
 
The F2TeTxLC construct was designed by introducing a spacer (2x, 64 bp) linked to a 
TEV protease recognition site (21 bp) and an N-degron (41 bp) followed by another 
spacer sequence (26 bp). SF3b155 (143) sequence was also fused to this and linked to the 
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N-terminus of the F1TeTxLC sequence. The new sequences were derived from the 
plasmid pCT251 (Taxis et al., 2009). The first Xcm1 site in F1TeTxLC was removed for 
easy cloning. The 825 bp long sequence was ordered from GENEART and the generated 
sequence was cloned into a kanamycin resistance vector backbone called pMK-RQ to 
generate the plasmid named 1077563_F2-TeTxLC_pMK-RQ. The engineered gene 
fragment was cut out with Pme1/EcoN1 and sub-cloned into the vector pAAV-Ptetbi-
F1TeTxLC/tdTOM in which part of the F1TeTxLC was cut out with Pme1/EcoN1. The 
new construct was named pAAV-Ptetbi-F2TeTxLC/tdTOM. 
By replacing tdTOM with TEV protease sequence by a directional BamH1/Xho1 cloning 
strategy, an additional F2TeTxLC was generated with the TEV in the same bidirectional 
cassette.  
 
 
4.2.5 Other rAAV constructs used in this study 
 
The plasmid pAAV-hSYN-TeTxLC-2A-mKO was created by PCR amplification of the 
1.3 kb TeTxLC fragment with 51EcoR1 and 31 Xho1 from the plasmid pAAV-Ptetbi-
TeTxLC/tdTOM. The fragment was cloned into pAAV-hSYN-tTA-2A-mKO (Tang et 
al., 2009) by 51 EcoR1 and 31 Xho1 sticky end ligation, by replacing tTA. 
To generate the plasmid   pAAV-Ptetbi-fLUC/tdTOM, firefly luciferase was 
excised from the plasmid pB1-5 (Baron et al., 1995) with Pst1/Xba1. The 1.6 kb fragment 
was blunted and ligated into the vector pAAV-Ptetbi-iCre/tdTOM (by the removal of iCre 
with HindIII/SphI followed by blunting). Likewise the plasmid pAAV-hSYN-rLUC was 
generated by excising the 947 bp fragment from the plasmid pRL-CMV with Nhe/Xba1. 
The fragment was cloned by blunt-end ligation into pAAV-hSYN-EGFP (by the removal 
of EGFP with BamHI/HindIII).  
 
 
4.2.6 Preparation and purification of recombinant adeno-associated viruses (rAAVs) 
 
4.2.6 .1 Transfection of HEK293 cells for virus production 
	   	   Materials and methods  	  
	   88	  
 
HEK293 cells were grown in DMEM supplemented with 10 % FCS and 50 mg/l 
penicillin/streptomycin in 5 % CO2 at 37 oC. Transfection was performed by calcium 
phosphate method with 50 µg total DNA per 15 cm plate. 
 
 
4.2.6 .2 Virus harvesting and purification via Heparin column 
 
Plasmids corresponding to rAAV constructs were individually co-transfected with pDp1 
and pDp2 (ratio 2:1:1) helper plasmids in HEK293 cells (Grimm et al., 2003, Zhu et al., 
2007). Forty-eight hours after transfection, cells were harvested by scraping and pulled 
into 50 ml falcon tubes. The cells were resuspended in 45 ml of 20 mM Tris 150 mM 
NaCl buffer (pH 8.0), frozen immediately in liquid nitrogen and stored overnight at -70 
oC. Cells were thawed at room temperature (RT) and incubated at 37 oC with 40 U/ml of 
Benzonase (for the degradation of unpacked DNA) and 0.5 % NaDOC for 60 minutes 
with frequent mixing. Lysed cells were spin at 3900 rpm for 15 minutes and the 
supernatant collected into new falcon tube and frozen at -70 oC overnight. The next day, 
the supernatant was thawed and spin for 15 minutes at 3900 rpm. The supernatant was 
run through a pre-equilibrated 1 ml heparin column (from Amersham, Freiburg, 
Germany). The column was serially washed with 20 ml of 100 mM NaCl 20 mM Tris 
(pH 8), 1 ml of 200 mM NaCl 20 mM Tris (pH 8) and 1 ml of 300 mM NaCl 20 mM Tris 
(pH 8). The virus was eluted serially with 1.5 ml of 400 mM NaCl 20 mM Tris, 3 ml of 
450 mM NaCl 20 mM Tris (pH 8) and 1.5 ml of 500 mM NaCl 20 mM Tris (pH 8). The 
eluted virus solution was collected into a 15 ml Amicon Ultra concentrator. The virus 
was washed at least two times with PBS by filling the tubes and spinning at 3200 rpm for 
2 minutes. The virus was concentrated further into a final volume of 250 µl and filtered 
through 0.2 µm Acrodisc column. 10 µl of the purified virus was loaded on 10 % SDS 
gel. Purified viruses were stored at -80 oC for long-term storage in 10 µl volumes.  
To determine the functional virus titer, dissociated neurons were infected with 
serially diluted viruses and fluorescently labeled cells were counted. For more details on 
virus preparation, see (Heindorf and Hasan, 2011). 
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4.2.7 Coomassie Blue staining of proteins  
 
10 µl of purified virus was loaded onto a 10 % SDS PAGE with 2.5 µl of 5x Lämli 
buffer. The gel was run at 130 V and 400 mA for about an hour. The gel was stained for 
45 minutes with Coomassie blue and destained for another 45 minutes. Successful virus 
purification resulted in the observation of 3 bands on the gel corresponding to the viral 
proteins 87 kDa VP1, 73 kDa VP2 and 62 kDa VP3. 
 
 
4.2.8 Infectious virus titer determination 
 
Primary hippocampal neurons were prepared from E18 rat embryos according to the 
protocol designed by (Brewer et al., 1993) and plated at 5x104 in 24 well plates were 
infected in vitro four days after preparation, with different volumes of rAAVs. Two 
weeks after infection, the highest dilution at which fluorescent cells were present was 
used for titer determination by counting. Six 10 x magnification fields were photographed 
and the number of fluorescent neurons counted. This number was multiplied by the ratio 
of the total well surface area to the 10 x field area and divided by the volume of virus 
applied. This yielded the number of neurons infected per microliter of virus. 
 
 
4.2.9 Infection of rat organotypic brain slice culture and dissociated neurons with 
         rAAVs 
 
Organotypic brain slices were prepared from rat embryo according to an existing protocol 
(Stoppini et al., 1991). Slices were infected with different rAAVs by directly dropping 
0.5-1 µl of the viral cocktail onto the tissue. Tissue media were changed at least 5 days 
after infection and subsequent media changes were done every 2-3 days. After two weeks 
of virus infection, tissues were either harvested for Western blotting, quantitative 
luciferase assay or fluorescent microscopy. Dissociated neurons on the other hand were 
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infected by adding 1 µl of virus cocktail into the media. Two weeks after virus addition, 
cells were lysed for quantitative luciferase assay or used for viral titer determination.  
 
 
4.2.10 Quantifying gene activity and expression pattern 
 
4.2.10 .1 Dual luciferase assay 
 
Dissociated primary neurons (or rat organotypic slices) derived from rat embryos were 
infected with rAAV-Ptetbi fLUC/tdTOM and rAAV-hSYN-rLUC. Two weeks later, cells 
in 24-well plates were lysed with 100 µl of passive lysis buffer (Promega, Madison, 
USA) per well. Twenty microliter of cell lysates were used for the measurement of the 
firefly and renilla luciferase activities using the Dual-Luciferase® reporter 1000 assay 
system (Promega, Madison, USA). In brief, the firefly luciferase and renilla luciferase 
assay were performed sequentially in one reaction tube. 100 µl of Luciferase Assay 
Reagent II (LAR II) was dispensed into all tubes sufficient for the total number of assay 
to be performed. The luminometer was programmed to perform a 5-sec premeasurement 
delay, followed by a 10 second measurement period for every reporter assay. 20 µl of the 
cell lysates was carefully transferred into the tube containing the 100 µl of LAR II and 
mixed gently by pipetting 3 times.  The firefly luciferase activity measured was manually 
recorded. This was followed by the immediate addition of Stop and Glow reagent and 
vortexing. The tube was returned into the luminometer and the renilla luciferase activity 
measured. 
 Luciferase activity was measured for 15 seconds using the Biotic® Lumi-10 
luminometer (Macherey-Nagel). Inducible firefly luciferase activity was normalized with 
the renilla luciferase activity from the same cell lysate and Dox-controlled gene 
expression was quantified as fLUC/rLUC.  
 For detailed dual luciferase reporter assay protocol, refer to Dual-Luciferase® 
Reporter Assay System protocol instructions for use of products e1910 and e1960 
(Promega USA). 
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4.2.10 .2 Time course of Dox dependent gene activation by firefly luciferase 
 
Dissociated primary neurons were infected with rAAV-Ptetbi fLUC/tdTOM, rAAV-
hSYN-tTA and rAAV-hSYN-rLUC for two weeks in 24 well plates. Wells were put into 
groups of four. To each group was added 1 µg/ml of Dox to shut down tTA dependent 
gene activation. The different groups were harvested over a period of time spanning 0 
minute (-Dox) to 2880 minutes (48 hours of Dox).  Quantitative firefly/ renilla luciferase 
activities were measured as described above. The same experiment was performed with 
the rtTA system. In brief, dissociated neurons were infected with rAAV-Ptetbi 
fLUC/tdTOM, rAAV-hSYN-rtTA and rAAV-hSYN-rLUC for two weeks, followed by 
incubation with 1 µg/ml Dox. Cells were harvested for luciferase activity measurement 
over a period of 0 to 48 hours. 
 
 
4.2.10 .3 Repeated cycles of Dox-dependent gene activation and inactivation 
 
 To investigate repeated cycles of gene activation, dissociated primary neurons were 
infected with either rAAV-Ptetbi fLUC/tdTOM, rAAV-hSYN-tTA and rAAV-hSYN-
rLUC or rAAV-Ptetbi fLUC/tdTOM, rAAV-hSYN-rtTA and rAAV-hSYN-rLUC. Wells 
of cell were grouped as before and each group was incubated with or without Dox over 
48 hours. The Dox treated medium was replaced with another conditioned medium 
without Dox also for another 48 hours. This was repeated for five cycles of Dox addition 
or withdrawal. The removal of Dox was done by washing three times with conditioned 
medium without Dox. At the end of the cycles, cells were harvested for luciferase assay.  
 
 
4.2.10 .4 In vivo luciferase assay with brain lysates 
 
 To measure luciferase activities from brain lysates, wild-type mice were injected with 
either rAAV-Ptetbi fLUC/tdTOM + rAAV-hSYN-tTA and rAAV-hSYN-rLUC or rAAV-
Ptetbi fLUC/tdTOM + rAAV-hSYN-rtTA and rAAV-hSYN-rLUC. Two weeks after virus 
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infection, mice were either injected with Dox (rtTA injected mice) or without (tTA 
injected mice) for forty-eight hours. The mice were anaesthetized with isofluran and 
decapitated. Brain regions infected with the viruses were carefully dissected and frozen in 
liquid nitrogen. These brain extracts were later sonicated and 20 µl of each extract was 
used to measure firefly luciferase  and renilla luciferase activities as described above.  
 
 
4.2.10 .5 Bioluminescence in vivo imaging in the living mouse 
 
Wild-type mice were injected with the viruses: rAAVPtetbi-bLUC + rAAV-hSYN-tTA 
into the cortex of one brain hemisphere while the other hemisphere was injected with 
rAAV-hSYN-bLUC. Two weeks after virus injection, mice were anesthetized with 
ketamine/xylazine, injected with an aqueous solution of D-luciferin (100 mg/g) and 
placed into a light-tight chamber. The emitted photons were acquired by a photon 
counting camera (2-stage ICCD C2400-47) fitted with a Nikon lens (35 mm/f1.2) and a 
computer with image analysis capabilities (Contag et al., 1997). Ten minutes after D-
luciferin injection, the chamber was closed and the photon counting program was 
initiated for a periods of 1–5 min. Photons were collected over time and the generated 
images converted to pseudocolor, digitized with the Argus 20 image processor 
(Hamamatsu). The intensity of acquired images was calculated as relative luminescent 
units per minute (rlu/min). 
 
 
4.2.11 β-galactosidase assay 
 
Transgenic Rosa26R mice were injected with rAAV-Ptetbi-iCre/tdTOM and hSYN-rtTA 
for two weeks. Paraformaldehyde fixed brain slices (100 µm) were prepared by 
vibratome sectioning. To visualize β-galactosidase activity, fixed brain slices were 
incubated in X-gal solution (5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 2 mM MgCl2, 2 mg/ml 
X-Gal in dimethylformamide / 1x PBS) at room temperature for 30-60 minutes. Sections 
were washed three times in 1x PBS, once in 10 mM Tris-HCl pH 7.5, mounted on glass 
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slides with Aqua Poly/Mount (Polysciences, Inc., Warrington, PA, USA) and protected 
with cover slips. 
 
 
4.2.12 Immunohistochemistry  
 
Immunostaining was carried out on wild-type mice (infected with rAAV-hSYN-TeTxLC-
2A-mKO), NR1-2lox transgenic mice (infected with rAAV-Ptetbi-iCre/tdTOM and 
rAAV-hSYN-rtTA). In brief, mice were anesthetized by isoflurane inhalation followed 
by intracardial perfusion with warm 1x PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4/2H2O, 1.4 mM KH2PO4) and 4 % paraformaldehyde (PFA) in 1x PBS prior to 
decapitation. Brains were removed and post-fixed in 4 % PFA at 4 oC overnight, followed 
by embedding in 2.5 % agarose (in PBS). 60-100µm vibratome coronal sections were 
prepared (VT1000S, Leica, Wetzlar, Germany) and stored in PBS supplemented with 
0.01 % sodium azide at 4 oC. Some sections were directly analyzed by fluorescent 
imaging after mounting with Aqua Poly/Mount (Polysciences, Inc., Warrington, PA, 
USA) and covered with cover slips. 
Tissues for immunostaining were blocked in 4 % normal goat serum (supplemented with 
1 % bovine serum albumin (BSA), 0.3 % Triton X-100). Sections were incubated 
overnight at room temperature in primary antibodies diluted in 1x PBS/ 1 % BSA/ 1 % 
normal goat serum/ 0.3 % Triton X-100. The antibodies used were anti 2A 1:2000 (rabbit 
polyclonal, Millipore), anti-Cre 1:1000 (rabbit polyclonal or mouse monoclonal, 
Covance, Germany), and anti-NeuN (mouse monoclonal, Chemicon, California USA). 
The next day, sections were washed twice in 1x PBS/ 0.3 % BSA/ 0.1 % Triton X-100 
(D2) followed by anti-rabbit or anti mouse FITC secondary antibody (1:200, Jackson 
Immuno Research) for 1 hour at RT. Slices were washed in 1x D2 buffer followed by 1x 
wash in PBS and mounted with Aqua Poly/Mount on glass slides with cover slips. 
Immunostained sections were analyzed with an Axiovert 200 M confocal microscope 
with LSM 5 PASCAL (Zeiss, Jena, Germany) coupled to 543 nm HeNe and 450-530 nm 
Argon lasers (Lasos Lasertechnik GmbH, Germany). 
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4.2.13 Protein extraction and Western blot analysis 
 
Protein analyses by Western blot were done by either transfecting HEK293 cells for 48 
hours or by infecting rat organotypic slices for two weeks with viruses. HEK293 cells 
were transfected with the following plasmids: pAAV-hSYN-TeTxLC-2A-mKO, pAAV-
Ptetbi-HATeTxLC/tdTOM + pAAV-hSYN-tTA, pAAV-Ptetbi-F1TeTxLC/tdTOM + 
pAAV-hSYN-tTA, pAAV-Ptetbi-F2TeTxLC/tdTOM + pAAV-hSYN-tTA and pAAV-
hSYN-EGFP. 48 hours after transfection, cells were harvested in lysis buffer (50 mM 
Tris-HCl, pH 7.6; 5 mM MgCl2; 130 mM NaCl; 10 mM KCl; 1 % Triton X-100; 5 % 
Glycerin supplemented with protease inhibitor complex, (CompleteTM, Roche, 
Mannheim). In the case of infection, rat organotypic slices were infected with the 
following viruses: rAAV-hSYN-TeTxLC-2A-mKO, rAAV-Ptetbi-TeTxLC/tdTOM + 
rAAV-hSYN-tTA, rAAV-Ptetbi-F1TeTxLC/tdTOM + rAAV-hSYN-tTA and rAAV-
Ptetbi-F2TeTxLC/tdTOM + rAAV-hSYN-tTA.  
 Rat organotypic slices were harvested in cold lysis buffer, two weeks after virus 
infection and homogenized by sonication. Protein concentrations were determined by 
Bradford assay. 15 µg of the protein lysates from both rAAV infected and uninfected 
tissues and lysates from HEK293 transfected cells were separated by SDS-PAGE (15 % 
separating and 6 % stacking gels) then transferred onto nitrocellulose membranes. 
Transfer onto membranes was done overnight at 30 V and 90 mA followed by blocking 
of the membrane in 5-10 % fat-free milk in 1x PBS for 1 hour. Western blots were 
probed with the following primary antibodies either overnight at 4 oC or 2 hours at RT: 
polyclonal rabbit anti-2A-peptide, (1:2000, Millipore), VAMP-2 (1:1000, rabbit 
polyclonal, abcam), cellubrevin (1:1000, rabbit polyclonal, abcam). Polyclonal goat anti-
synaptotagmin (1:500, Santa Cruz), synaptophysin (1:500, goat polyclonal, Santa Cruz), 
monoclonal mouse anti- β-tubulin (1:1000, Millipore), VAMP1 (rabbit polyclonal, 
abcam), mouse monoclonal anti-GFP  (1: 1000, Clontech) and monoclonal mouse anti-
HA (1:1000, abcam). The secondary antibodies used were; horseradish peroxidase-linked 
anti-rabbit, anti-goat or anti-mouse (1:15000, Vector Laboratories, Peterborough, UK). 
Western blots were detected by enhanced chemiluminescence kit (ECL kit, Amersham 
Pharmacia Biotech, Freiburg, Germany). 
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4.2.14 Stereotactic virus injection into the mouse brain 
 
Six weeks old mice (C57BL/6), Rosa26R and NR1-2lox, were deeply anesthetized 
(Ketamine 100 mg/kg, and Xylazine 5 mg/kg), and secured in a Kopf stereotaxic setup 
(Kopf Instruments, California, USA). The foreskin on the skull was cut open to expose 
the skull. With the help of a drill, small holes (about 50-100 µm) were drilled into the 
head of the mice at different coordinates as stated below. Approximately 300 nl volume 
of viral suspension was stereotaxically injected via glass pipette (tip diameter 10-20 µm) 
into each spot chosen to be injected. The ∼300 nl virus was injected in a total time of at 
least 2-5 minutes and a waiting period of 5 minutes before the next injection or the 
withdrawal of the injection needle. After injection, the skin was sutured and the wound 
disinfected. Newly injected mice were kept on heating blocks at 37 oC until they woke up 
and were fed on wet food. For details on injection, see (Cetin et al., 2006). 
The coordinates used for the different injections with reference to the bregma were 
(Paxinos and Franklin, 2001):  
 
(1) Somatosensory cortex:     -1.70 mm bregma 
       1.5 mm lateral 
       500 µm deep 
 
(2) Hippocampus     -1.70 mm bregma 
       1.5 mm lateral 
       1.5 mm deep 
 
(3) Barrel Cortex     -1.5 mm bregma 
       3 mm lateral 
       500 µm deep 
 
(4) Striatum (unilateral)    0 mm bregma 
       2.2mm lateral 
       1.7mm deep 
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(5) Medial septum (bilateral)    0.5 and 1.2 mm bregma 
       ± 0 mm lateral  
       4 and 4.5 mm deep 
 
(6) Motor cortex (bilateral)     + 0.1, + 1.0, and + 1.9 mm bregma 
       ± 1,  ± 1.5, and ± 1.75 mm lateral 
       0.6 mm deep 
 
 
4.2.15 Fluorescence and confocal imaging 
 
Light and fluorescence imaging were performed with Zeiss Axioplan2 (Carl Zeiss, Jena, 
Germany) with the camera system AxioCam HRC with magnifications ranging from 2.5x 
to 40x dry or 63x oil immersion objectives (software: Axiovision 4.8.1). A compact light 
source (Leistungselectronic Jena, Germany) with 488 nm and 568 nm filters. Confocal 
images were acquired with Zeiss LSM PASCAL confocal laser scanning microscope 
equipped with an Argon laser (457,476, 488 and 514 nm) and a Helium Neon laser (543 
nm) with objectives 5x-40x dry and 63x oil-immersion objective. Images were analyzed 
with ImageJ and LSM image browser.  
 
 
4.2.16 Amphetamine-induced rotational behavior in mice 
 
D-amphetamine (AMP) sulfate was dissolved in sterile 1x PBS at 10 mg/ml and further 
diluted to 0.5 mg/ml (working concentration) in sterile saline for intraperitoneal 
injections (i.p.) (5 mg/kg). TeTxLC virus injected mice and control virus (hSYN-Venus) 
injected mice were later injected with a single i.p. of amphetamine (5 mg/kg body 
weight). Ten minutes after amphetamine injection, mice were placed in an open field box 
(50 x 50 cm) for locomotor activity studies. Locomotor activity was recorded with a top-
mounted camera connected to a video tracking system. Each mouse was allowed to move 
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freely in the open field for 10 minutes. Recordings were done before and after 
amphetamine injection. The movie files were analyzed using the VideoMot software. The 
total number of 360o rotations made by the animals was manually counted and mice 
tracking paths were also documented. A rotation was scored when the mouse make a 
continuous 360 o circle without change in direction. Only ipsilateral rotations were 
counted. Movements made around the periphery of the box were not counted as a 
rotation. 
 
 
4.2.17 Tail suspension test (TST) 
 
Tail suspension test is one of the commonly used test to study antidepressant behavior in 
mice (rodents) (Steru et al., 1985). In this work, I used a modified version of the TST to 
investigate the behavior of mice with unilateral lesion to the striatum. Mice with virus 
injected unilaterally to the striatum were suspended by the tail for one minute and their 
twitching behavior monitored by video recording and visual observation for one minute. 
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